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The aim of this study is to determine the rate at which UVB radiation takes effect in order to 
produce an effective regimen for treatment. 
Psoriasis, a chronic, proliferative, inflammatory disease that is under genetic and 
environmental control is the major condition where UVB radiation successfully reduces 
symptoms. 
The treatment regimen for at present involves exposure doses that are increased 
alogarithmically and is based upon previous broadband knowledge. No established protocol 
for TLO 1 UVB phototherapy exists. 
Patients were randomly chosen from Drybum Hospital Phototherapy Department. Baseline 
minimal erythemal measurements were calculated (MED0) and random measurements were 
taken during the course using a single TLO I lamp. Data was collected over a period of I year 
and the effects of photoadaptation were determined. Factors considered include the period of 
time in between treatments, the number of treatments already attended and cumulative doses. 
MED ratios were calculated and analysed to produce a skin adaptation model. The majority 
of patients were phototested 2-6 times during the treatment course, which lasted 6 weeks 
(mean). Results indicated that missing a treatment session was insignificant to the rate of 
tolerance. 
The model for tolerance was calculated to be: 
Tn= 1 + 3 [1- exp (- 0.03n)] n = tolerance following n treatments 
A revised protocol was established and a clinical trial implemented. Protocol results 
indicated that the new regimen significantly reduced cases of burning and significantly 
reduced the cumulative doses of radiation. Revised protocol patients (yellow group) received 
total doses of 12.7 J/cm2 (median) and the original regimen provided a total of 16.9 J/cm2 
(median). There was no significance in the time length of the treatment protocols. 
The revised protocol is therefore significantly more suitable because it reduces chances of 
excessive erythema discomfort and by reducing the radiation exposure doses the regimen 
also reduces the risk of skin malignancies. 
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1 UN!TRODUCTION 
1. 1 Anatomy and Physiology of the Skin. 
Changes that occur in the skin as the result of treatment can only be 
understood if the physiology and anatomy of the skin are known. 
The normal epidermis is a terminally differentiated squamous epithelium, 95% 
of the cells being keratinocytes, which become pigmented through the donation 
of melanin from melanocytes. The epidermis can be divided into 4 distinct 
regions based upon the morphology of the cell. 
stratum basale or stratum germinativum (basal eel/layer) 
stratum spinulosum (spinous/prickle eel/layer) 
stratum granulosum (granular eel/layer) 
stratum corneum (keratin cell layer 
The stratum basale tends to be only 1 cell thick but in glabrous or 
hyperproliferated dermis the thickness may increase to 2-3 cells, all of which 
are capable of cellular proliferation. These small columnar cells {1 0-14nm) 
contain many ribosomes, an elongated nucleus and dense tonofilament 
bundles, indicating very high levels of protein synthesis. As the cells move from 
the dermis towards the surface they alter in morphology and function. At the 
stratum spinosum the cells flatten and the nucleus becomes condensed. The 
cytoplasm contains less RNA and the cells begin to become keratinized. The 
cells contain numerous desmasomal connection plaques or prickles that allow 
stable connections throughout the layer and they are capable of mitotic division 
as demonstrated during proliferative and malignant conditions. At the granular 
layer the nucleus becomes lost and organelles become lysed in an organised 
fashion. Once the cells reach the granular layer masses of granular shaped 
keratohyalin granules can be seen, arranged in rows within the cytoplasm. The 
stratum spinosum and the granular layer also contain laminated vesicles {100-
300nm). These granules become important in the stratum corneum for cellular 
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adhesion and barrier functions because their lipid contents are released into 
the intracellular space. Stratum corneum cells (corneocytes) are keratinized by 
the release of keratin from the granules under the influence of filaggrin. 
Filaggrin has been shown by histochemical and biochemical studies to be a 
basic protein rich in histadine and lacking in sulphur (Reaven et al 1965). 
Profilaggrin, a high molecular weight phosphorilated protein is contained in the 
keratohyalin granules and upon release is converted to its aggregate form by 
specific phosphatases. Filaggrin interacts with keratin causing filament 
formation, which is reproducible in vitro (Dale et al 1978). Keratin is a 
multistranded a helix stabilised by disulphide bonds of cysteine sulphydryl 
groups, hydrogen bonds and Van der Waal forces. Filaggrin is degraded as the 
cells move towards the stratum corneum and the amino acid products are 
involved in skin water retention. 
Corneocyte membranes develop membrane-associated proteins, which are 
insoluble, and cross-linked (Simon et al 1987). lnvolucrin (95kDa) is the soluble 
precursor, assembled by the action of epidermal transglutaminases e.g. 
glutamyl lysine. If involucrin is labelled, cell differentiation rates can be 
measured and analysis of diseases such as psoriasis can be examined (Dover 
et al 1987).0ther proteins have also been found to associate with the 
keratinocyte membrane. These include loricrin, which is a 70% glycine and 
serine, and 8% cysteine protein. At the stratum granulosum level the loricrin 
granules can be seen by immunogold labelling and they reach the cell 
periphery by the stratum corneum stage. A 21 OkDa and 95kDa protein have 
also been isolated and these combine with non-specific proteins to form the 
insoluble cornified envelope. At this stage in the cell differentiation process, 
desmosomal connections also become degenerated. These symmetrical 
junctions have a core of 30nm and are composed of cadherin proteins; 
desmoplanktin I (250kDa), desmoplanktin II (220kDa), desmocalnin (240kDa), 
desmoplakin Ill (83kDa) and desmoplakin IV, depending on the epithelial type 
(Ebling et al 1992). 
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The horny or keratin layer is the first line of defence and forms a durable 
barrier, which maintains the water content of the skin at 10-20%. The 
keratinised dead cells are continuously being sloughed off and lubricated by 
cellular transpiration and sebaceous and sweat secretions. It is thought that the 
presence of a granular layer is necessary for a significant keratinisation and it is 
only in the presence of hair follicles that a true granular layer is formed. In 
glabrous skin the keratin is thick and is found to be associated with sweat 
glands rather than hair follicles (Ebling et al 1992). 
There are also many other types of cells in the epidermis and the dermis which 
have specialised functions. There is an intricate blood vessel system in the 
dermis supplying nutrients, oxygen and other essential products to the skin and 
removing any waste products. The blood vessels are also involved in supplying 
a rich number of white blood cells to the dermis and epidermis, e.g. neutrophils, 
monocytes and lymphocytes, which prevent infection of foreign substances 
through phagocytosis, interleukin production (released by neutrophils to raise 
body temperature and stimulates the liver to uptake iron and therefore reduce 
the availability of iron for bacterial cell division)and interferon release (released 
by some cells in response to viral attack and interferes with the replication of 
viral DNA and RNA). Specific lymphocytes and complement proteins are also 
made available so that cell mediated and humoral immune responses can 
occur. Among other effects this stimulates the production of antibodies by 
lymphocytes , which in turn have a number of effects, such as opsonisation (the 
binding of micro-organisms and stimulation of complement), lysin production 
(stimulation of the lysis of micro-organisms), agglutination of microbes and 
neutralisation of toxins e.g. diphtheria or tetanus. Memory T cells are also 
available, stored in the lymph nodes, in order to allow a rapid response to any 
subsequent invasion from antigens. In the dermis there are complex supporting 
apparatus consisting of elastic and collagen fibres. It is in-between these fibres 
that the macrophages, lymphocytes and fibroblasts of the dermis are 
contained. 
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Mast cells can be isolated from tissue in the upper dermis and stimulation leads 
to exocytosis if histamine granules. Histamine causes inflammation, increasing 
the blood supply to the tissue and therefore increasing the number of white 
blood cells in the area in order to fight off infection. Somatosensory neurones, 
hair follicles and glands are also abundant in the dermis. The glands include 
sweat glands, sebaceous glands, tear glands and mammary glands. The gland 
cells move up into the epidermis and onto the surface of the skin where they 
secrete their products. They have their own stem cells and patterns of cell 
renewal. The somatosensory neurones include various sized neurones with 
different nerve endings that are involved in sensing such as pain, flutter, warm 
or cold stimuli. The nerves take the stimuli to the brain stem, spinal cord, 
thalamus and cerebral cortex and it is the nerve endings that respond to the 
different stimuli e.g. mechanoreceptors such as the raffini corpuscle, the 
pacinion corpuscle or the meissners corpuscle, nocireceptors which have bear 
endings that respond to pain and thermoreceptors which respond to warmth 
and cold (Berne & Levy 1990). 
1.2 The Aetiology of Psoriasis. 
The actual cellular mechanisms that lead to psoriasis are complicated and not 
fully understood. T cells are known to play an important role in inflammation 
and cell growth through the release of particular cytokines that act directly and 
indirectly upon keratinocytes. If we look at the histology of psoriasis, the cells in 
the germnative layer are twice as thick as normal and the cell cycle is altered in 
length. Normally the epidermis maintains a constant thickness because of the 
balance between cell division and cell loss. Various factors work in 
collaboration to maintain this equilibrium. Cell growth stimulants and inhibitors 
are particularly important. Stimulants include epidermal growth factors, proteins 
that stimulate keratinocyte division directly, transforming growth factor that acts 
upon the keratinocyte in an autocrine manner, basic fibroblast growth factors, 
platelet derived growth factors and insulin like growth factors. Inhibitors are 
termed chalones and are produced by suprabasal cells. By acting directly at the 
stratum basale level they increase the turnover time of the keratinocyte. The 
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exact point of inhibition is unknown and chalones include transforming growth 
factor J3, pentapeptide (glut-asp-ser-gly-ala), a and J3 interferons and tumour 
necrosis factor. In psoriasis the balance between eel! growth and cell loss is 
disturbed and the subsequent plaques are formed. Keratinocytes, T cells, 
dermal, epidermal, antigen presenting cells, macrophages, 
polymorphonucleocytes, mast cells, endothelial cells fibroblasts, smooth 
muscle cells and nerves are all implicated in this condition. They are thought to 
act together in an integral and complex manner but the actual mechanisms are 
unknown. 
In conditions such as psoriasis the keratin layer becomes disrupted. The water 
balance of the skin is altered and the skin becomes reduced in its ability to 
function as a protective barrier. Psoriasis is a common chronic, proliferative, 
inflammatory disease, which is under genetic and environmental control. 
Genetic Factors 
Psoriasis is well established as being under genetic control and various genes 
are known to be involved in its expression. The major locus that has been 
isolated is the HLA gene cluster. Epidemiological surveys of populations 
indicate that psoriasis affects 1.5-3% Western Europe and Scandinavian 
populations. It is due to epidermal hyperproliferation, inflammation and vascular 
changes in the skin. Watson et al in 1972 performed surveys that showed 46% 
of relatives and 1.2% spouses of psoriatic patients also present the 
condition. 16% of children had psoriasis when 1 parent had the condition and 
only 7.8% when neither parent was inflicted. Both TNFa and 013 genes have 
been identified in the HLA gene cluster, the HLA cluster being found on 
chromosome 6 position 21. 3. There are a variety of functions carried out by 
these molecules including stimulation of the expression genes for other 
cytokines, their receptors and transcription factors. TN Fa, like IL 1 induces 
ICAM, MCAF and IL8 and is thought to be primarily produced by the cy1okine 
as well as by macrophages and other cells. TNFa's bioactivity is increased in 
psoriatic keratinocytes and leads to the stimulation of hyperplasia. Recent 
evidence produced by Tomfohrde et al in 1994 also indicates there may be 
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genes on the distal long arm of chromosome 17. With the human genome 
project underway a world wide search for the function of all genes is in process, 
so hopefully in the near future the genetic control of psoriasis and many other 
conditions will be better understood. 
Envin:mmentaf Factors 
There are many environmental factors that influence this condition. They exert 
their effects through biological means. Some of these conditions are described 
briefly below: 
1.2. 1 Skin trauma 
In those who suffer from psoriasis it has been well observed that skin trauma 
takes a lot longer to heal { up to 3 times the recovery length) and scarring is 
much more commonplace. Also at the site of an injury psoriatic plaques may 
develop. Such injuries include physical, chemical or electrical trauma, surgery 
scars, infective and inflammatory damage. The reaction tends to occur 7-14 
days after the incident and may lead to spreading of the disease to a wider 
area of the body. The reaction is all or none and because the psoriasis is 
capable of spreading, humoral factors are thought to be involved (Eyre et al 
1984). 
1.2.2 Infection 
In 1964 Whyte et al demonstrated that streptococcal infection plays an 
important role in the stimulation of psoriasis and administration of antibiotics 
e.g. erythromycin/penicillin and rifampicin leads to a significant psoriatic 
improvement in many patients (Rosenberg et al 1986). It is thought that the 
streptococcal infection produces a major immune response that leads to 
increased levels of white blood cells in the skin, particularly neutrophils 
(confirmed through biopsies). The most common psoriasis produced in this way 
is guttate but other forms may also be worsened through infection. Removal of 
the tonsils in prone children may also prevent recurrence (Whyte 1964). 
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1.2.3 Endocrine Factors 
Reports have shown that during hormonal changes e.g. puberty and 
menopause, psoriatic exacerbation increases (Ingram 1954).1n a study 
performed on pregnant patients, 40% showed improvement, and 15% 
worsened during pregnancy. After birth 50% degenerated and 10% of the 
patient's skin condition improved. High doses of oestrogen may also 
exacerbate this condition by unknown mechanisms (Ebling 1992, Dunna 1989). 
1.2.4 Metabolic Factors 
Diabetes mellitus patients often find that prolonged or recurrent hypoglycaemia 
may flare psoriasis. Psoriatic patients who are unable to control their blood 
sugar levels effectively are therefore much more likely to express the disease 
than those who are capable of blood sugar maintenance. Diabetics have higher 
levels of glucose in the tissue than normal and regular deviations in 
concentration will lead to metabolic alterations and increased cell turn over 
rates (Hunter 1995). 
1.2.5 Sunlight 
Although for the majority of patients sunlight helps their skin, evidence 
suggests that about 5% of patients are worsened by sunlight and have more 
severe psoriasis during the summer months. 40% of these patients are 
diagnosed as polymorphic light eruption patients and psoriasis is classed as a 
secondary condition. The people who suffer most from this problem tend to be 
the elderly, females and those with skin type 1(never bum always tan) (Ebling 
1992, Ros et al1987). 
1.2.6 Drugs 
Beta Blockers. Both f31 and j32 adrenergic receptor blockers may lead to certain 
skin conditions erupting e.g. lichenoids, eczema and psoriasis. Eruption 
normally occurs approximately 5 days after the drug is administered and is due 
to keratinocytes possessing rh receptors on their cell surface. Inhibition of 
stimulation in this way leads to reduced [cAMP]i and [Ca++]i. Reduction of 
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these intracellular messengers stimulates an increase in cellular proliferation 
and reduces cell differentiation. p blockers are given for conditions such as 
angina arrhythmia, hypertension, postmyocardial infarction, migraines, 
essential tremors and thyrotoxicosis (Abel et al 1986). 
Lithium Carbonate Normally administered as a prophylactic to sufferers of 
psychotic depression, lithium carbonate reduces the intracellular sodium 
concentration though displacement Reduced sodium levels leads to reduced 
intracellular cAMP and lowering of the cAMP levels are interpreted by the cell 
to increase cell proliferation and reduce cell differentiation. Lithium carbonate 
also increases the number of polymorphonuclearcytes in epidermal and dermal 
circulation, it increases their motility and their phagocytotic activity and this too 
leads to hyperproliferation (Barth et al 1986). 
Antimalarial Drugs In 1950-60 it came to light that antimalarial drugs e.g. 
quineurine, chloroquine and hydroxychloroquine aggravate psOiiasis. Research 
into the mechanisms of aggravation have failed to produce a valid answer but 
anti-inflammatory mechanisms and immunosuppressive effects have been 
reported in vitro with chloroquine (Ebling 1992). 
1.2.7 Psychogenic Factors 
There is an established connection between the emotional state of the patient 
and the severity of the psoriasis. Psychological stress may lead to exacerbation 
of the condition but the state of the patient may lead to a reduced ability to cope 
with or administer their treatment. It could therefore be a more indirect 
mechanism of aggravation than a direct one (Baughman 1971). In 1940-1970s 
experiments involved epidemiological studies and Farber et al (1968) found 
40% psoriatic patients expressed the condition during times of stress. Other 
studies related the appearance of psoriasis to major incidents e.g. illness, 
sexual assault or death (Gatson 1987). The most recent studies accept 
psoriasis is affected by stress and have attempted to define the connection in 
physiological terms. The body responds to stress by stimulating the adrenal 
gland, anterior pituitary and the cerebral cortex. Stimulation reduces 
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lymphocytic, neutrophilic and natural killer cell activity. It increases adrenaline 
release, blood glucose levels and may lower serum cortisol levels leading to a 
flare in psoriasis (Duller 1986). There is also evidence that the nervous system 
can be an influence, releasing local neuropeptides e.g. substance P which acts 
on mast cells to initiate inflammation (Ginsburg 1995). 
1.2.8 Alcohol 
it appears that alcohol may iead to an increase in the severity of psoriasis. 
Studies have found that psoriatic patients drink more than the average person 
and Gupta et al (1993) found alcohol abuse reduces the effectiveness of 
particular therapies including UVB light therapy, dithranol and steroid treatment. 
Alcohol breaks down in the body to form toxins that are concentrated in the 
blood. The skin becomes flushed during alcohol consumption and this 
aggravates the inflamed psoriatic lesions. In the long term, the calories in 
alcohol may lead to overweight problems and the increased body folds are 
prone to sweating and flaring of psoriasis. Alcohol also leads to reduced zinc 
concentrations which is necessary for skin healing and excessive drinking may 
lead to liver damage which increases the side effects of prescribed drugs e.g. 
methotrexate. The side effects include haematological, hepatic and 
gastrointestinal toxicity (Monk et al 1986). 
1.2.9 Cigarette smoking 
For those patients who smoke there appears to be a dose responsive 
relationship between the number of cigarettes smoked and the development of 
psoriasis. The numbers could correspond to the amount of stress in the 
person's lifestyle and therefore be related to psychological factors rather than 
the direct effect of the tobacco smoke. Smoking reduces the effectiveness of 
the immune system and can often lead to throat infections that trigger psoriasis. 
The chemicals that are contained in the tobacco also interfere with the healing 
responses of the skin (Dave 1997). 
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1.2.1 0 Acquired Immunodeficiency Syndrome (AIDS) 
Studies have demonstrated that there is a significant reiationship between 
AIDS and psoriasis. Some patients experience psoriasis for the first time after 
contracting the HIV virus whilst others experience extreme flaring of the 
condition. The effect that AIDS has upon psoriatic skin is unknown but 
because treatment normally involves immunosupressive drugs, treatment can 
be difficult. Psoriasis appears to be greatly improved by the administration of 
cyclosporin which inhibits T helper cells function (Ebling 1992) and a recent 
study involving acitretin found that the administration of this drug is effective 
and safe. The adverse effects are also tolerable e.g. pruritus, hair loss, dry skin 
and cheicitus (Buchheri et al1997). 
1.3 The immunology of psoriasis 
UVB was originally thought to act directly upon the keratinocyte but further 
evidence suggests direct action upon the immune system and inflammatory 
cells. Examination of psoriatic plaques confirms the presence of several 
cytokines e.g. interleukin 1, 2, 6 ( IL 1, IL2, IL6), chemokine, IL8, MGSA/gro, 
TNFa and severai growth factors including insulin-like and EGF-Iike growth 
factors Bos et al1988). 
I shall now describe some of the different cytokines and their role in the 
biochemical alterations that occur during psoriasis. 
1.3.1 IL 1,2,3,4,5 and CSFs 
Normal skin contains high levels of IL i. Psoriatic activity increases IL 1 mRNA 
and intracellular protein concentrations. !L 1 receptors are also increased, 
particularly in the basal layer. I L2 levels become raised in psoriatic plaques and 
experiments show exogenous introduction of il2 leads to plaque formation. 
Studies have not, however, found increased bioactivity of IL2. Mature T cells 
produce IL4 and IL5 and mast cells are able to release IL3, 4,5 and GMCSF 
and experiments involving cultured keratinocytes have found that IL3 or a 
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similar molecule is produced by these cells. It is highly likely that all these 
molecules are present in psoriatic plaques but whether they are pmduced by 
keratinocytes or other cells are not known. They are thought to play a major 
role in cutaneous inflammation and stimulating the survival and function of 
Langerhans cells (Lee et al 1988). 
1.3.2 IL6 
il6 has many functions in the body, one of which is as an autocrine mitogen in 
psoriatic epidermis. IL6 mRNA is not raised in lesions but reports have found 
increased activity at plaque margins. T cells have been shown to induce IL6 
production in cultured keratinocytes and it primarily activates B cells. The actual 
functional role of IL6 is debatable may be involved in hyperplasia and 
inflammation (Hunter 1995). 
1.3.3 Interferons 
INF-Iike antiviral activity is increased in psoriatic lesions, being due to INFa in 
the basal layer and dermal cells and INFy in the stratum corneum, mononuclear 
cells and endothelial cells. Intradermal injection of INFy leads to psoriatic lesion 
production in susceptible patients and increases in 'normal' individuals INFy is 
suggested to act directly on keratinocytes to produce hyperplasia (Nickoloff 
1988). 
1.3.4 Chemokines 
IL8 and gro peptides are known to be active in psoriasis. mDNA for these 
molecules are in ver1 high levels in keratinocytes and are very bioactive. Their 
function is not fully understood (Hunter 1995). 
1.3.5 Growth Factors 
Many EGF-Iike growth factors are over expressed in psoriatic lesions and 
evidence indicates that they act in an autocrine manner to cause hyperplasia in 
the lesional area and the surrounding skin. Inflammatory cells are also thought 
to be stimulated by EGF- like growth factors (Nanney et al 1986). Insulin-like 
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growth factors are found in raised concentrations in the basal and suprabasal 
layer of psoriatic lesions and in vitro experiments indicate they act directly upon 
keratinocytes to stimulate growth. However, it is not known if psoriatic 
keratinocytes express insulin-like growth factors. Fibroblast growth factors 
(FGFs) have been reported in large concentrations in psoriatic plaques and are 
involved in wound healing. By acting in a paracrine manner on keratinocytes 
and are probably involved in the inflammation and blood supply of the lesions. 
Platlet derived growth factors (PDGFs) stimulate connective tissue production 
but they do not stimulate keratinocytes in vitro. Receptors are found, however 
on cells in the papillary dermis where they may stimulate dermal cells to 
release other keratinocyte mitogens (Bauer 1986). 
1.3.6 Neuropeptides 
NGF, prolactin and vasoactive intestinal peptide (VIP) are 3 neuropeptides that 
potently stimulate in vitro keratinocyte growth. NGF binds to high and low 
affinity receptors and acts autocrinely but it has never been isolated in psoriatic 
plaques. Prolactin is highly mitogenic for keratinocytes but there is no evidence 
of its expression during this condition. VIP is found widely in the central and 
peripheral nervous system and increases 6 fold in psoriatic lesions. Studies 
have found that cytokines produce their effects by acting through multiple 
pathways. But in psoriasis they are thought to have effect by increasing 
intracellular concentrations of cAMP (Halprin 1975, Marcelo et al 1979). It is 
thought that immunological alterations that occur in psoriasis actually increase 
the cAMP concentrations. The increased cAMP levels induce gene 
transduction and cell growth and lead to the production of the characteristic 
red, raised lesions. cAMP exerts its effects through activation of cAMP-
dependent protein kinases (cAMPPKs). There are 3 known mammalian 
cAMPPKs that effect cell growth and abnormal cAMPPK type 2 is thought to be 
responsible for psoriatic hyperplasia (Tounier et al1995). 
Therefore the expression of psoriasis and its effects upon the skin are very 
complex. Many inflammatory and immune cells play important roles in the 
stimulation of this condition and many chemicals interact to produce the typical 
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symptoms of psoriasis. The major effect of these chemicals is to produce 
inflammation, increase cell growth and stimulate an immune response. The 
biochemicals are thought to exert their effects through raising cAMP levels and 
many experiments have involved immunosuppressants in order to determine 
the role of cAMP. In 1996 Ockenfels et al used cyclosporin A and FK 506 to 
inhibit secretion of T cell cytokines and cAMP levels were measured prior to 
and during incubation. The study found that the keratinocyte proliferation rate is 
decreased by the introduction of cyclosporin A and FK 506 due to a reduction 
in cAMP formation and the consequence is suppression of psoriasis. cAMP 
activates intracellular pathways that lead to cell proliferation. FK506 reduces 
intracellular cAMP and therefore plaque formation. 
1.4 Ultraviolet Radiation Physics 
The electromagnetic spectrum ranges from radiowaves through to X rays and 
gamma rays. The optical radiation part of the spectrum can be split up into the 
component wavelengths by passage through a prism but it was not until 1802 
that Johann Retter discovered radiation beyond the visible spectrum, which is 
now termed ultraviolet. Ultraviolet radiation is classified as the region from 
400nm to 1 OOnm and can be further subdivided into 3 groups, although the 
divisions of these wavelengths are variable to some degree: 
UVA 400-320nm 
UVB 320-290nm 
UVC 290-200nm 
Ultraviolet radiation is emitted spontaneously by the sun and stars and can be 
artificially produced for irradiation by, for example, gas discharge lamps such 
as the low pressure mercury arc lamp (Diffey 1982). 
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1.4.1 Ultraviolet Radiation Sources 
The most effective wavelengths for phototherapy of psoriasis range from 295-
320nm and modern lamps reflect this. Of al! ultraviolet radiation, UVB (290-
320nm) has the most therapeutic effect upon psoriasis and UVC (200-290nm) 
produces erythema but with no therapeutic effect (Anderson et al 1984). For 
many years there were no specific lamps available and lamps designed for 
other purposes were used. Today, there is a choice of specialist lamp systems 
available, produced by several manufacturers. In 1974 the Task Force on 
Photobiology reviewed PUVA and UVB equipment (Harber et al 1974). In 1981 
Horwitz and Frost expressed the significance of uniform light distribution during 
treatment with fluorescent bulbs. They reported that fluorescent tubes do not 
have a constant output along their length, the output being greatest in the 
centre. The trunk is more sensitive to UV than the lower limbs so lesions in this 
area (ie trunk) clear more effectively. They concluded that tubes should be 
arranged to accommodate this but the problem is overcome in our department 
through standing the patient on a stool to raise the legs 1 Ocm from the floor. 
1.4.2 Phototherapy Equipment 
There are several types of equipment available and ultraviolet lamps can be 
classified into 2 groups according to the mechanism of ultraviolet production: 
Medium/high pressure mercur/ arc lamp 
Ultraviolet radiation (UVR) is produced when an electrical current is passed 
through a gas (vaporised mercury). The mercury atoms collide with the 
electrodes and they move to a higher transitional state. On returning to the 
resting state the atoms release the excess energy as UV, visible and infrared 
radiation. The wavelengths and intensities of the radiation depend upon the 
pressure in the lamp and the addition of a metal halide e.g. lead iodide or iron 
iodide alter the spectrum emitted so that appropriate spatial emission is 
enhanced. A glass filter can also be fitted in front of the lamp to reduce the 
emission of wavelengths below 290nm. The trouble with this, however, is that 
the glass filter alters its transmission depending upon the temperature and the 
lamp must reach thermal equilibrium (approx. 20 minutes) before the patient 
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can be exposed to the light. Examples of arc lamps are the Alpine sunlamp 
and Hohensonne lamp. The arc lamps are stacked in vertical columns of 
usually 5 lamps/column and 2-4 columns are arranged to provide uniform 
irradiance during treatment. 
Fluorescent lamps 
This is a mercury vapour lamp that is coated with phosphor. The mercury, at 
low vapour pressure, emits radiation at the wavelength of 253. 7nm The 
phosphor coated glass envelope absorbs the radiation and re-emits it by the 
process of fluorescence at either visible, UVA or UVB wavelengths, depending 
upon the chemical nature of the phosphor. Examples of UVB fluorescent 
lamps are Philips TL01 (narrow band), Philips TL 12 (broad band}, Sylvania 
UV12 (broad band), and Sylvania UV6 (broad band). The fluorescent cubicles 
incorporate up to 48 lamps, 2m in length mounted in a cabinet that encloses 
around the patient or a bed that houses 28 lamps arranged in an anterior and 
posterior canopy. 
UVB cabinets come in two forms, those that feature a built in fuliy electronic 
measuring and dosing meter and those that have a timing control only. For the 
timed cabinets extra equipment is necessary to calibrate the machine and 
ensure the lamps output, so that accurate treatments can be administered. This 
is done using hand held radiometers. The output of the lamps depends upon 
the amount of usage, the temperature, the warm up time and mains voltage. 
When high and medium mercury pressure lamps are switched on there is an 
excess of liquid mercury in the lamps and it takes several minutes for thermal 
equilibrium to be reached and the mercury to vaporise. Once the tubes are 
switched off they can not be restarted for 30 minutes and therefore the 
machines remain switched on throughout the clinic. Fluorescent lamps may be 
switched on and off without any problem but work most efficiently at 25°C, 
establishing a steady output after 1 minute. As temperature increases the 
output from the tubes decreases so fans are incorporated into the machines to 
maintain temperature. New lamps exhibit a running in time. That is when the 
lamps are first switched on they produce a high output which quickly 
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deteriorates to a steady output at an equilibrium. For fluorescent lamps this 
period lasts 100 hours and for mercury arc lamps it takes only 20 hours. As the 
usage progresses the radiance from the lamps gradually decreases. Both the 
cabinets with built in sensors and those without possess pros and cons. With 
the cabinets that do not have built in radiometers, training of personnel and the 
frequent reading of the irradiance is time consuming and there is always a 
danger of the radiometer malfunctioning or giving inaccurate readings due to 
incorrect calibration or the sensor being covered during reading. The 
relationship between prescribed dose, measured irradiance and exposure time 
is: 
Exposure time (minutes)= [1000 x Prescribed dose (J/cm2)] I [60 x lrradiance (mW/cm2)] 
If the sensor is built into the cabinet it must be cleaned at regular intervals to 
ensure dust does not build up in front of the detector leading to lowered 
readings and an increased risk of burning patients. As previously described the 
lamps do not emit uniformly along their length and the detectors only sense 
light from one area. This could lead to false readings, however, because the 
sensors always read the same area of the tube. Patients must also be warned 
that they must not touch the sensors or obstruct them in any way because this 
will lead to increased exposure time and burning. This is always a potential 
problem in these cabinets because once the patient is inside the cabinet their 
activities are unknown. It must also be remembered that the sensors, like the 
UV tubes deteriorate in time. This too could lead to problems if not realised. For 
these reasons I believe the timed cabinets to be safer and more reliable. There 
are also cabinets available that possess both UVB and UVA tubes. These 
cabinets are convenient in that they enable a choice of spectrum to be 
available for patients and they take up less space than 2 separate cabinets. But 
the lamps are more widely spaced than the separate machines and the 
dangers of administering the wrong waveband of UVR could have serious 
adverse effects. 
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1.4.3 PUVA Equipment 
PUVA equipment has been available for approximately 20 years in Britain and 
like UVB cabinets they contain fluorescent tubes. PUVA lamps emit at 315-400 
nm, peaking at 352nm (Diffey & McKinlay. 1983). like UVB there are a variety 
of machines available, ranging from whole body to extremities units and the 
lamps are almost always used in conjunction with psoralen tablets as 
photochemotherapy. Psoralen is normally administrated in the form of tablets 
but may also be given in cream, gel or lotion form or put into a bath. The lotions 
only become particularly useful if the extremities are being treated because it 
means the patients do not have to ingest the psoralen which makes their eyes 
sensitive to UVA and may make them feel nauseous. The starting doses for 
PUVA have been revised over the years and it is now recommended to use 
0.25-4.0 J/cm2 depending upon the skin type. However the validity of skin 
typing is now debatable and it is possible that UVB sensitivity is not as skin 
type related as was once thought (Rampen et al 1988, Cox et al 1989). 
1.5 Ultraviolet Effects on Normal Skin 
UVB produces hyperplasia, tanning, oedema, sunburn cell induction, itching, 
cis uronic acid {cis UCA) formation, immune responses and inflammation. 
1.5.1 Hyperplasia and Tanning 
These are important protective mechanisms that prevent further penetration of 
UV radiation. Tanning reduces the risk of developing basal and squamous cell 
carcinoma and people with a lower potential for tanning are more at risk of skin 
carcinoma. Tanning is due to melanocytes producing melanin in melanosomes. 
The melanosomes move through the cell dendrites and transfer the melanin 
into neighbouring keratinocytes. The transferred melanin forms a protective 
layer over the outer aspect of the keratinocyte nucleus and protects against 
UVR (mainly 290-320nm) by acting as an energy sink and free radical 
scavenger. Melanin is produced in 2 forms: 
eumeianin (the most common form, black-brown in colour) 
phaemelanin (the less common form, yellow or red in colour) 
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1.5.2 Oedema 
A protective mechanism brought about by excessive UVR. Langerhan ceils, 
dendritic antigen presenting cells, are thought to be the initial immunological 
line of defence. They engulf antigens, transport them to lymph nodes and 
present them to the T lymphocytes. Psoriasis is thought to stimulate Langeran 
cell production and treatment with UVR reduces numbers and 20-40% lose 
their dendritic capability. Broad band UVB has been shown to reduce dendritic 
cell accumulation 48 hours after irradiation. Some experiments suggest TNF-a 
and dendritic cells are not produced by narrow band UVB. 
1.5.3 Erythema/Sunburn Reaction 
Painful erythema is more likely with UVB than PUVA. For UVB the maximum 
erythema occurs 8-24 hours after administration and for PUVA maximum 
erythema is at 72-96 hours. Erythema is due to increased blood flow in the sub 
papillary of the dermis and begins to occur 1-4 hours after exposure. The 
erythema is caused by cellular damage through photochemical reactions which 
leads to vasodilatation. If erythema is severe DNA may become damaged and 
inflammatory mechanisms become initiated. Inflammation also causes 
vasodilatation and oedema may occur due to the release of epidermal 
hydrolases. Mitosis becomes inhibited for 24-36 hours, after which a massive 
stimulation occurs that decreases after a few days. Epidermal thickening, by up 
to 50-60%, is due to an increase in the number of proliferating basal cells and 
hypergranulosis and hyperkeratosis results. Increased numbers of melanocytes 
are also present in the epidermis (Marks 1996). 
Mild burning is normally treated with moisturising cream, analgesics and topical 
steroids. Paste bandages may be used for severe burning/blistering. 
1.5.4 Itching 
This is a common problem and reduced with emollient application. 
Antihistamines may be prescribed for severe cases to reduce the inflammation. 
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1.5.5 Cold sores (herpes simplex) 
This virus may be stimulated by UVB radiation in some patients who already 
harbour the vin.ts and the usual applications of topical treatment is employed. 
The more severe, long-term side effects of phototherapy include chronic actinic 
damage, dyskeratosis, skin cancers, immunological alterations, photoageing 
and cataract formation. For these reasons phototherapy departments 
administer the minimum UVR dose possible to each patient and cover body 
parts that do not need treating e.g. using a visor, wearing a T shirt or being fully 
clothed if only the face is being treated. I now intend to describe photoageing 
and cancer risks in more detail. 
1.5.6 Photoageing 
Long term administration of UVR has been found to lead to thinning of the skin 
and premature ageing. Ageing can be defined as a reduction in the functional 
capacity of the skin and can be classified into two categories. 
® intrinsic ageing which occurs in all skin and is only slightly altered in 
appearance. 
o premature ageing which leads to rough, wrinkled skin that may be 
irregularly pigmented and have undergone elastosis, lacking in tensile 
strength and possess solar comedones and actinic keratoses. Ageing 
occurs at the cellular level and can be characterised according to the skin 
typing. 
Types 1 & 2 
Freckling 
Telangiectasia and /or fine wrinkles 
focal diffuse anthropy with irregular depigmentation 
Actinic keratoses and /or irregular hyperpigmentation 
Types 3. 4 & 5 
diffuse hyperpigmentation 
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lentigines 
elastosis with coarse/shallow skin 
severe elastosis with deep furrows. 
Elderly peoples' skin cells are less efficient at perceiving and responding to 
extracellular signals due to reduced receptors and signal transduction pathway 
levels. When UVR causes DNA damage, the cell differentiation process is 
thought to be reduced in functional ability and evidence suggests that 
melanocytes become altered in density during photoaging. UVR also leads to 
the formation of irregularly pigmented areas e.g. ephilides (which are 
brown/yellow in appearance and macular), actinic lentigines (an area where 
keratinocytes and melanocytes are damaged and the epidermis is 
hyperpigmented due to an increase in the number of melanocytes and the 
histology of the skin is altered. They possess great potential to becoming 
malignant) Lentigo maligna (lesions which are brown/black/white and slowly 
increase in size with a great risk of developing into malignant melanoma) and 
hypomelanoses (which are due to the epidermis becoming reduced or lacking 
in melanocytes} (Ortonne 1996). 
After long periods of ultraviolet exposure the elastic tissue becomes damaged 
by a pror..-ess known as elastosis_ There are two views as to how this occurs_ In 
1992 Shafetter-Kochanek claimed UVR exposure leads to the release of 
growth factors from the damaged epidermal cells and these chemicals 
stimulate fibroblasts to release elastic tissue elements that are constructed in 
an abnormal and rapid manner. Braverman ( 1982) proposed the other 
alternative which is that the normal collagen is degraded and replaced with 
abnormal elastin. The damaged skin tissue is unable to support the peripheral 
blood vessels and passive dilation occurs which is seen as a flushed 
appearance in the patient. I consider this view to be more realistic, based on 
my own knowledge that similar abnormalities can be seen in autoimmune 
diseases such as osteoarthritis which is due to degradation of hyaline cartilage 
through the action of antibodies. The elastic collagen fibres become replaced 
with nonelastic fibrous collagen which is ineffective as a shock absorbing 
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cartilage (J.P.Pearson, unpublished data).Cartilage like skin, is composed of a 
basic matrix of collagen. Collagen is a triple helix polypeptide, assembled as 
procollagen molecules which become chemically linked in the fibroblastic cell's 
cytoplasm. It is then released by exocytosis into the extracellular fluid where it 
becomes assembled into a complex interlocking matrix. Within the matrix is a 
ground substance. The ground substance of skin is composed of 
glycosaminoglycans and that of cartilage is protein and glycosaminoglycans. 
The molecules are covalently and noncovalently bound to form proteoglycans. 
Each proteoglycan contains 50-1 00 side chains of glycosaminoglycans which 
have large numbers of hydrophilic carboxyl and sulphate groups attached and 
because of this over 60% of the net weight of the cartilage is water. 
The collagen and ground substance of both the skin and cartilage provide 
tensile strength, resilience to stress and pressure and to absorb forces applied 
to the surface. 
There are three types of cartilage found at the end of the bones, walls of the 
trachea, in the larynx and nasal septum. 
1) hyaline cartilage - very hydrophilic, 70-80% water, very elastic, spongy and 
mouldable. Found at ends of long bone. 
2) Fibrous cartilage - consists of thick bundles of collagen and acts as ashock 
absorber in the tendons, ligaments, symphysis pubis and inbetween the 
vertebrae. 
3) Yellow cartilage - consists of a dense network of collagen fibres with 
flexibility and strength. Found in the external pinna, epiglottis and eustachian 
tube. 
If hyaline cartilage becomes damaged eg. through antibody attack or through 
traumatic damage there are two processes by which repair occurs. 
1) Intrinsic repair - Where the damaged tissue and chondrocytes are 
replicated and the matrix is repaired. 
2) Extrinsic repair - where severe damage causes mass degradation and the 
cells proliferate and produce fibrocartilage and cartilage. The repaired 
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cartilage is more fibrous than the original tissue and less efficient a~ weight 
baring which can lead to more structural damage. This is very similar to the 
degradation process described by Braverman in 1982 and because of the 
similarities in chemical composition between skin and cartilage, I suspect it 
to be most probable (Hughes et al1987). 
1. 5. 7 Skin Cancer 
Skin cancers include melanoma, basal cell carcinoma and squamous cell 
carcinoma. UV damages the DNA of cells, particularly the pyramidine dimer 
and repair is normally 99.99% successful, however, if the damage is not 
repaired tumour promotion may occur. The carcinogenic effects of UVA and 
psoralen have been known for many years and in 1979 Tam et al produced 
evidence to link psoriatic PUVA patients and skin cancer. Psoralen itself has 
not been found to be carcinogenic but a study performed in 1982 suggests 8-
methoxypsoralen may cause cancer to the kidneys, ~ungs and subcutaneous 
tissue in rats (National Institute of Health). The doses administered however 
were up to 75 times greater than those given to humans so the significance of 
this study is disputable. UVB has been established as carcinogenic in humans 
for decades but several studies have shown UVB to be relatively safe. 
(Grupper et al 1980, Larko et al 1982). Stem et al (1980) examined cases of 
psoriatic cancer patients and found that patients exposed to 300 treatments or 
more have a 4. 7 times greater risk of developing cancer than those who have 
had little or no UVB treatment. 
It has been suggested that been reported to lead to increased reports of genital 
tumours in men. Stern et al in 1990 found the risk of squamous cell carcinoma 
in those receiving PUVA/UVB treatment the incidence of cancer can be 
reduced depending upon the protocol of UV administration (Henseler et al 
1981). In 1979 Stem et al published the results of an extensive study that 
suggested PUVA may promote basal cell carcinoma and squamous cell 
carcinoma in patients who are genetically predisposition or at risk from other 
factors, rather than being a carcinogen in its own right. Young reviewed the 
carcinogenic effects in 1990 and found that because psoralen binds reversibly 
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to DNA causing unstable crosslinks, it is therefore highly mutagenic and 
potentially carcinogenic. PUVA has also to be 96 times more likely to develop 
genital tumours than the general population. The risk is dose dependent and it 
is therefore common practice to cover the genitals during therapeutic treatment. 
The group also compared the protocols for PUVA administration in Europe to 
America. In comparison to Europe, Americans administer PUVA over longer 
periods of time at lower doses. Studies comparing cancer prevalence between 
these 2 places indicate the American regime to be more carcinogenic. Such 
comparisons can be problematic because geographical location, genetic 
predisposition, prior exposures to carcinogens, prior histories of carcinomas, 
and skin types are confounding factors. 
The adverse effects of phototherapy are minimised by undertaking several 
preliminary precautions. The patients who are selected must not be at high risk 
from developing cancers. Such patients include those with a history of skin 
cancer, previous arsenic treatment, those previously exposed to ionising 
radiation and those who have been previously prescribed antimetabolites e.g. 
hydroxyurea, cyclosporin A and methotrexate. However, administration is 
obviously at the doctor's discretion. Through the administration of drugs e.g. 
retinoids a lower dose of radiation can be given which could be beneficial to 
many patients who may be receiving high cumulative doses. The safety 
threshold for photochemotherapy (PUVA) is 200 treatments or 1200 J/cm2. 
Yearly examination of patients skin is a sound idea and patients should be told 
to avoid the sun when ever possible. During PUVA treatment protective glasses 
should be worn for 24 hours to reduce the risk of cataract formation. The use of 
sunscreen and clothing to areas that are not necessary to be treated is also 
sensible. 
1.6 The Effects Of Ultraviolet Radiation On Psoriatic Skin 
Psoriasis stimuiates the production and circulation of cytotoxic lymphocytes, 
particularly natura! killer cells (NKCs), and T cells e.g. CD56+, CD16+, C02+, 
CD116+, CD3- and CD 25+ and CD3+, respectively. The main function of 
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these cells is to protect against foreign bodies and to reduce tumour cell 
formation. UVR probably exerts its effects by reducing epidermal T cells and 
NKC function. 
The effects of UVB upon T cells was studied in 1995 by Kreuger et al using a 
protocol similar to the Goekerman regime. (A regimen that involved the 
application of crude coal tar to the skin and then exposing the patient to UV 
radiation.) In all 9 cases the psoriasis became exacerbated (P<0.001). The 
psoriatic plaques reduced in thickness by 43-80% {P<0.001) and keratinocytes 
proliferation decreased by 69% (p<0.001). Biochemical analysis of the lesions 
found that a3 integrin, which is expressed basally and suprabasally, becomes 
predominantly basal following phototherapy and T cells also become 
significantly reduced. CDS+ lymphocytes decrease in the epidermal-dermal 
interface and upper papillary dermis and CD3+ cells reduce by 70-100%. CD1+ 
lymphocytes, however, appear to actually increase in the epidermal psoriatic 
lesions. 
Psoriatic keratinocytes produce HLA-DR and ICAM-1. Analysis of these 
proteins during psoriasis exacerbation found that there is little or no expression 
of these molecules following phototherapy treatment. The effects of therapy 
upon T cells are thought to be selective to the affected areas and repeated 
exposure does not reduce the number of cells further. The effect upon NKCs 
was studied by Gilmour in 1993. The study involved 20 patients with chronic 
plaque psoriasis and 3 with guttate psoriasis. In comparison to 11 normal 
patients there was no significant increase in NKC activity but after 4 weeks of 
TL01 treatment activity was significantly decreased and began to increase after 
treatment had discontinued. After 4 weeks of stopping treatment the activity 
level still had not reached the original level. The group suggested that NKC 
inhibition is dose and wavelength dependent and mechanisms of control are 
unknown but may be due to: 
• direct action on the cells as they circulate in dermal capillaries leading to 
functional damage 
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o UVR stimulates the release of a soluble mediator which enters circulation 
and effects NKC function e.g. Prostaglandin 
o Cis-UCA in the epidermis may be produced by conversion from trans-UCA 
via UVR. On exposure 60% UCA is converted and leads to dose dependent 
suppression of NKCs, possibly by down regulation of the secondary 
messenger system of NKCs (Gilmour 1993).UVR also reduces psoriatic 
plaques by inhibition of omathine decarboxilase activity and is known to 
lead to elevation of PKC activity in mice fibroblasts. 
1. 7 The History of Phototherapy 
The original forms of phototherapy date back over 3000 years when the Greeks 
used the sun to treat certain skin conditions and topically applied plant extracts 
to improve pigmentation. In the 1700s rickets was common and it was found 
that the sun helped to prevent this condition, although the skins function in 
vitamin D production was not understood. Light was also used to treat skin and 
bone tuberculosis and today heliotherapy is still used in certain areas of the 
world eg. The Dead Sea where people travel hundreds of miles to receive its 
healing powers. The sun was the original source of UV radiation, having an 
MED of 20 minutes at midday in June at 41 o latitude. The significance of this 
source of UVR is the fact that it is free, however, the variations in weather 
coupled with seasonal changes in solar UV intensities in Britain, it is an 
unrealistic therapy, so other alternatives are provided by the NHS. In other 
parts of the world heliotherapy is very important in the treatment of psoriasis. In 
Israel The International Psoriasis Centre has established a complex which 
consists of clinics, shops, hotels and restaurants so that sufferers may undergo 
a course of heliotherapy within a 'holiday'. The treatment involves sunbathing 
each day in accordance with a regime and daily bathing in the Dead Sea. 
Creams are applied frequently throughout the day under the guidance of 
trained nurses and dermatologists. The Dead Sea is 400m below sea level and 
the majority of erythemal-causing UVB rays are removed by increased passage 
through the atmosphere and because there is a high evaporation rate which 
leads to a very humid environment. These factors enable patients to bathe in 
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the sun for longer time periods than normal and thus, the centre is extremely 
beneficial in many cases. The Dead Sea contains 300g/l salt and patients 
return with increased skin tissue levels of magnesium, calcium and potassium 
and raised circulatory concentrations of bromine and selenium. But whether 
these compounds are also important in the treatment is unknown. 
A major breakthrough in the therapeutic use of light came from Neils Finsen in 
1890 through his treatment of tuberculosis with carbon arc lamps and his 
treatment of lupus vulgaris with the same equipment earned him the Nobel 
Prize in 1903 (Diffey 1982). Following Finsen's work came the work of Alderson 
in 1923, proposing the beneficial use of the newly invented mercury vapour 
lamp. 
The first recorded form of crude PUVA in the western world came from Axmann 
in 1918 who used oil of bergamot on unpigmented areas of skin and vitiligo was 
treated similarly but with psoralen in 1948 by El Mofty. The breakthrough in 
systemic psoralen and UVA treatment came from the work of Parrish et al in 
1974. They published information that demonstrated the use of PUVA for 
psoriasis and a new form of treatment became available which is particularly 
important for treating premalignant and malignant conditions such as mycosis 
fungiodes, Nekams Disease and lymphomatoid papulosis, as well as psoriasis, 
eczema and light sensitivity conditions. 
UVB phototherapy was originally used in conjunction with other topical 
tre..atments e g_ tar, sulphanilamide and dithranol and at the beginning of the 
20th century UVB was not thought to be beneficial if administered alone (Ellis et 
al 1948). Epstein analysed UVB therapy in 1947 and concluded that UVB is 
completely ineffective in the treatment of psoriasis if the skin is not firstly 
sensitised. He found that administration of UVB 1-3 times/week accompanied 
with sulphanilamide and tar to be very beneficial. Ellis (1948) also found that 
UVB alone was ineffective but the paper he provided was not detailed enough. 
He did not describe regimes used or doses and the patients were only treated 
for 2 weeks at a time. It was also unclear if erythemal doses were administered. 
In 1925 Goekerman observed that coal tar topical treatment plus UVB therapy 
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produced increased beneficial effects to light therapy alone and he concluded 
that tar is a photosensitizer (Young 1972}. 
Another regime was described by Ingram in 1953. The protocol is similar to 
Goekermans except it involves coal tar paste, zinc oxide and paraffin, tar baths 
instead of soap and water or the use of undiluted picas carbonis instead of 
crude coal tar, all of which seem to produce better results. Treatment is 
repeated every 24 hours. The dithranol is an oxidising agent and burns the 
lesions and the stockinet acts as a compress to intensify treatment (Ingram 
1953). 
In 1970 Young et al performed experiments which indicated UVR tends not to 
be an essential part of dithranol treatment using lngrams regime and significant 
success can be achieved without UVR. 
In 1977 Parrish et al provided outstanding evidence that UVR can be 
successfully administered alone, if given to erythema. In 1976 Fischer 
performed experiments using different wavelengths of UV (313, 334, 365 & 405 
nm). The results indicated that treatment of psoriasis 5 times/week was most 
effective when erythema was produced at 313nm wavelength. Once it was 
universally accepted that different wavelengths of UV have different effects on 
the skin, studies involving manipulation of the spectrum were undertaken and in 
1981 Parrish and Jaenicke performed an exceptional study using 
monochromatic wavelengths of UV in psoriatic patients. The effect of 
wavelengths 254, 280, 290, 296, 300, 304 and 313nm were determined and 
the course was 24 treatments over 4 weeks. Results were examined and it was 
found that UVC has no therapeutic effect and easily produces erythema. 
Treatment with 296nm was found to have varying effects and in some cases no 
significant effect and in others, complete clearance. 300 and 304nm treatments 
produced clearance at doses equal to or just greater than the MED and 313nm 
completely resolved the psoriasis in all 4 patients. The authors concluded that 
UVC is phototoxic, UVB is very effective and can be used at levels less than 
MED, and UVA is ineffective at acceptable exposure times. Having identified 
the optimum wavelength for treatment, projects were initiated to produce a 
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more effective lamp and the narrowband UVB lamp was manufactured in 1984-
5 (Anderson et al 1984). 
1.8 The Practice of Plim~ochemothera~py (PUVA) 
Since it was established that phototherapy alone is beneficial a variety of 
regimes have been developed for UVB and PUVA. Although a relatively large 
dose of UV is given in the treatment of psoriasis it would be ineffective and 
dangerous to administer the dose in 1 treatment. Therefore the treatments are 
fractionated and cumulative doses are administered. Through fractionation the 
skin is allowed to adapt in order to allow greater increments to be given and the 
ultraviolet radiation has a progressive effect on the immune system, the 
keratinocytes and the inflammatory cells of the patient. 
1.8.1 PUVA Therapy 
PUVA is a combination of UVA radiation and the administration of photoactive 
chemicals - psoralen. Psoralens are a group of furocoumarin compounds that 
are isolated from particular species of plants e.g. lime, lemon, parsley, parsnip 
and celery. Once digested the psoralen reversibly binds to cytoplasmic 
membrane proteins throughout the body. Circulatory psoralen is degraded in 
the liver and excreted as an undetectable biproduct. The most frequently used 
oral psoralen is 8-methoxypsoralen isolated from Amni Majus and was 
originally used as a topical agent to treat leucoderma (EI Mofty 1948). PUVA 
can be administrated in 3 basic ways: tablet treatment, topical treatment or bath 
treatment and it is used to treat conditions including psoriasis, vitiligo, eczema, 
lichen planus, graft versus host disease, pityriasis lichenoides chronica, 
cutaneous T cell lymphoma (mycosis fungoides), urticaria pigmentosa and 
photosensitive disorders. In the treatment of psoriasis lesions usually clear 
within 6-8 weeks. 
Systemic Treatment 
8 methoxypsoralen (8 MOP) is the usual oral drug administered although S-
and 3-methoxypsoralen are also available and they normally have less severe 
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side effects than the 8-MOP alternative. Each 8-MOP tablet contains 1 Omg 
psoralen and the dose taken depends upon the patients weight. The usual 
dosage is 0.6mg/kg. 
The tablets are taken 2 hours prior to UVA administration because the 
maximum plasma concentration of 8-MOP occurs at approximately this time 
after ingestion. The side effects of psoralen include nausea, depression, 
insomnia, nervousness and dizziness. 
Psora/en Bath Lotion 
Some hospitals, including Dryburn Hospital, do not have bath PUVA facilities 
available. Bath psoralen is 1-1.2% solution in an aqueous base and the 
patients are required to soak in the bath of solution at 2.6mgll for 15 minutes. 
UV opaque spectacles are not necessary and the adverse effects of oral 
psoralen are not usually seen, however, potential buming risks are present if 
the psoralen is not carefully mixed in the bath water. 
Psora/en topical lotion/gel/paint 
PUVA lotion is 0.15% in aqueous solution, the paint is 1-0.15% in solvent 
solution and the gel is 0.005% in aqueous solution. The solutions are applied to 
affected areas as a thin film 15 minutes before irradiation and removed after 
treatment. No adverse effects are seen and application by a skilled 
nurse/physiotherapist rarely leads to burning through uneven distribution. 
Courses normally consist of 1 0-30 treatments over a period of 4-12 weeks. The 
frequency of exposure and the length of course depends upon the condition 
and the severity and is normally prescribed by the doctor. In some clinics the 
first dose of UVA is administered depending upon the patients skin type and 
the usual starting dose is 0.5-1J/cm2. Prior to administration of PUVA therapy 
patients are given a full blood count and kidney and liver function tests. This is 
not necessary for UVB treatment as oral tablets are not taken. Histological 
examination of the skin may be carried out in certain cases. Some practices 
perform a minimal phototoxic dose (MPD) test. MPDs are performed in a 
similar way to the MED measurements I am under taking for this project. The 
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patients have the procedure thoroughly explained to them for maximum 
efficiency and the test is performed on disease free skin, normally on the back, 
arm or buttock. The skin is exposed to UVA at varying doses, either through 
apertures containing attenuators with different sized holes or by covering the 
skin with a cloth/plastic sheet that contains a grid of holes of differing sizes. The 
resulting MPD is then used to determine the starting dose. If no erythema is 
seen, the patient is questioned as to whether the psoralen was taken correctly 
and, if not, the test is repeated. If the test was performed adequately a 30% 
increased dose can be administered as the first dose. For topical application 
70% MPD. is administered and the test is performed 15-30 minutes after 
application. The results are usually read 72 hours after the test is performed. 
PUVA is normally administered 2 times per week and erythema reaches 
optimum after 72 hours. Clearance of psoriasis normally occurs after 30 
treatments. 
1.9 The Practice of Phototherapy 
UVB is administered in a similar manner. Prior to treatment a MED test may be 
performed to establish a starting dose and 70% MED is safe to administer. The 
MED is established by the process similar to that described previously. For 
UVB therapy, erythema reaches a maximum 8-24 hours after exposure and 
therefore treatment may be given every day if necessai)l. However, 
administration normally occurs 2-3 times per week and clearance of psoriasis is 
seen after 20 treatments. 
1. 9. 1 Action spectrum for healing of psoriasis by phototherapy 
In 1981 Parrish et al determined the most effective wavelengths for the 
treatment of psoriasis using monochromatic radiation. They found wavelengths 
below 300nm to be very erythrogenic, 10 times more so than the 31 0-315nm 
range and the carcinogenic properties of UV radiation are also greater in these 
broadband lamps. (van V\/eelden et al 1984). Broad band lamps produce 
radiation in the region below 280nm and evidence indicates that UVC radiation 
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is ineffective in the treatment of psoriasis, producing burning rather than any 
therapeutic effect. (van Weelden et al 1980). Further studies suggest that the 
most effective wavelengths for treatment are 295-31 Onm and below 295nm the 
therapeutic effect is significantly reduced (Diffey and Farr 1996). 
In 1984 van Wealden and van der Leun demonstrated that the effectiveness of 
phototherapy could be much improved by the use of a narrow band of UVB. If 
UVC is reduced, so are erythema. This led to the development of the TL01 
lamps which produce emissions peaking at 311nm (± 2nm) and a smaller peak 
at 305nm. In 1986 van Wealden and van der Leun compared the efficiency of 
narrow band lamps to wide band lamps by treating one side of the body with 
broad band UVB and the other side with narrow band UVB. The patients were 
irradiated until erythema was produced. The results indicated that the narrow 
band lamps were significantly more effective in psoriatic treatment. (P=<0.05). 
1.9.2 TL01 Phototherapy 
The TL01 lamps use has steadily increased over the last 30 years. The dose of 
UVB that can be given during any one treatment is limited by the !eve! of 
erythema that exposure produces. Philips TL01 lamps emit a narrow band of 
UV radiation peaking at 311-312 nm. The lamp manufacturers altered the 
phosphors in the lamp rather than the filter glass itself in order to alter the 
energy distribution of the lamp. The success of the lamp is due to its ability to 
exclude shorter wavelengths of UV which are erythrogenic but do not benefit 
psoriasis. Lower exposure doses are required as the lamp is more intense and 
there is a potential for reduced cumulative doses if a successful regimen is 
produced but higher cumulations of radiation can occur because of the 
reduced erythrogenic effect of the lamp (Parrish 1981 ). 
Initially, regimens for the TL01 were incorporated from broadband protocols. 
Many studies have subsequently been undertaken over the past 20 years, 
involving analysis of regimens. The intent is to produce a suitable protocol with 
minimal cumulative doses, minimal painful erythema occurrences and minimal 
treatment sessions with maximum results (Van Wealden 1990). 
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There are 2 basic regimens for the use of TL01 phototherapy as outlined 
below. 
The most commonly used regimen involves a treatment programme where 
there is a starting dose of 0.3J/cm2 and subsequent stepwise increases e.g. 
0.3, 0.5, 0.9 J/cm2. The subsequent treatment dose depends upon the previous 
dose and the skin's erythemal reaction to it (no erythema, definite erythema or 
equivocal erythema). Patients move through the treatment chart until an 
erythemal response presents. The patient then moves down the chart receiving 
appropriate treatment doses. The treatment process is dependent upon patient 
feedback (see appendix 1 for treatment chart). 
The second treatment regimen involves MED (minimal erythema dose) testing 
the patient prior to treatment initiation. The MED is determined using a TL01 
lamp mounted into a phototesting apparatus. The MED is determined 72 hours 
post test and initial doses are administered at 70% MED. The increments for 
further treatments are 40%, 20% and 10% depending upon the extent 
erythema produced by previous treatment sessions and due to the patients skin 
type which is confirmed by taking a patients history and through objective 
determination of the skins melanin levels. Treatment continues until the 
patient's psoriasis is cleared to a suitable level (Collins 1995). 
Regardless of the method of administering phototherapy, during the treatment 
programme trained staff are required to assess the patient's progress in-
between treatment sessions. Skin typing, patient history, physical examination 
and verbal enquiries are all used to determine UVB radiation treatment levels 
during the treatment course (Gordon 1998). In 1994 Dootson performed a 
study that indicated that only 28% Phototherapy centres in the UK use this 
method of treatment. The initial UVB dose should be sufficient to ensure that 
the radiation has a therapeutic effect without causing excessive erythema. 
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It was Fischer in 1976 that suggested that this level is typically 70% of the 
MED. A study performed by Gordon et at in 1998 also demonstrated that skin 
typing alone can not be a successful way of determining a radiation programme 
or initial radiation doses. 
Many studies have been carried out in order to determine the therapeutic 
differences between TL01 Phototherapy and TL 12 and also comparing TL01 to 
PUVA. (A comprehensive table of comparative studies can be seen below.) 
Studies comparing Tl01 to TL 12 (e.g. Karvonen et al1989; Green et al 1988; 
Picot et ai 1992) have demonstrated that the TLO 1 lamp is superior in efficiency 
to the broad band TL 12 lamp. In 1986 and 1988 van Weelden et al performed 
studies that demonstrated how successful the Tl01 lamp is. In 1988 the study 
involved 10 subjects. 1 side of the patient was treated with broad band UVB 
and the other with narrow band. The patients were hospitalised and exposed to 
radiation from both lamps simultaneously. One lamp was situated at the back 
of the cabinet and 1 at the front. Therapy was performed 3 times/week for 10 
treatments in 8 patients and 2 times/week in 2 patients. The effects measured 
were based upon the amount of erythema produced, scaling decreases and 
severity of the condition after treatment. It was found that TL01 treatment was 
the more effective treatment of the two in 9 out of 10 patients (p<0.05). During 
this study they also compared the tumour promoting potential of the lamps 
through exposing mice to the lamps until erythema and oedema occurred. All 
animals developed tumours but those receiving TL 12 treatment developed the 
growths at significantly earlier stages in the treatment. (P<0.01). More recent 
studies contradict this information. Flindt Hanson ( 1991) performed irradiation 
studies on hairless mice 5 days/week for 30 weeks using TL01 and Tl12 
phototherapy. It was found that tumours appeared significantly earlier in TL01 
treated mice. Wulf (1994) and Gibbs (1995) also confirmed these results and it 
is now thought that TL01 phototherapy is in fact more carcinogenic than 
alternative broad band TL 12 treatment. This is because UVA is thought to play 
an important role in skin protection, possibly through enhancing the repair of 
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pyramidine dimers and reducing free radical formation. However, because the 
TL01 lamp produces results quicker and maintains remission for longer periods 
of time, these lamps still remain more popular in the majority of hospital 
phototherapy departments. A similar study was performed in 1996 by Gonzalez 
et al who determined the tolerance of human skin to UVB. The study involved 
90 patients with plaque psoriasis and MPEs were determined 24 hours after 
exposure to broad band UV. The test involved exposure to 15 apertures 1.3 em 
in diameter. The sites decreased in doses from 150-10 mJ/cm2 with increments 
of 10 mJ/cm2 each. Phototests were performed every 2-3 weeks and the 
patients were treated 4 times/week. The results indicate that the minimal 
perceivable erythema {MPE} increases rapidly in the first two weeks for all skin 
types and plateaux by the sixth week. The authors found that the MPE of those 
with an initial MPE of 20-50 mJ/ cm2 began to decrease again after the sixth 
week whereas those with an initial MPE of 60-1 00 mJ/cm2 remained constant 
until the eighth week. From the results a 'tolerance factor' {TF} was expressed 
as: 
where TFmax is the maximum value the tolerance factor might attain; t is the 
number of weeks of treatment; and -c is a characteristic time over which the skin 
develops 63% of TFmax. 
The group concluded that tolerance is due to hyperpigmentation, thickening of 
stratum corneum and probably a number of other complex factors that lead to a 
decrease in tolerance after multiple exposures. 
TL01 - PUVA studies have generally found the therapeutic effects of PUVA 
and narrow band UVB to be similar and UVB is more favourable due to the 
reduced post-radiation effects; clearance rates and cumulative dose levels 
were found to be insignificant but because psoralen consumption is not 
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required with UVB treatment, TL01 treatment is more favourable: eye 
protection is not required post-treatment, the patient does not feel dizziness or 
nauseous, there is a reduced drug cost implication and TL01 phototherapy is 
suitable for both pregnant ladies and children (Takew 1996). In 1990 van 
Weelden compared PUVA to narrow band phototherapy and found PUVA to be 
superior in treating in clearing lesions from the extremities whereas TL01 
therapy is more effective at clearing lesions from the trunk. 
In 1998 several studies compared regimens where low and high dose 
increments were administered. Clearance times, cumulative doses, severe 
erythema episodes and the number of treatments per week were all 
investigated and compared. The study of Hofer et al in 1998 involved 13 
patients who were treated 3-5 times per week. 11 patients completed the trial 
and the patients randomly received a low dose regime to one side of the body 
at 35% MED and the other side of the body received 70% MED. The results 
indicate that initially the response was better from the high dose treatment but 
as treatments continue a satisfactory response is seen through both treatment 
regimens. After 3 weeks of treatment the clearance level is actually equal from 
both treatment protocols and only 4 more treatments were required from the 
low dose regimen (16 rather than 12 treatments). The lower dose regimen 
acquired a significantly lower cumulative dose of radiation (9.4 J/cm2 as 
compared to 14.0 J/cm2 using the high dose regimen.) Therefore a lower dose 
regimen is much more advantageous. Wainwright performed another study 
involving the comparison of high and low dose increments in 1998. This half 
body study involved 20 patients being treated 3 per week. Half the body 
received 70% MED for the initial treatment and then 40%, 20%, 20% or 0% 
increases depending upon the erythemal response. The other half of the body 
received the low dose regimen, which involved delivery of 70% MED, followed 
by 20, 10 or 0 % MED radiation dose increments. Again, subsequent dose 
levels depended upon post treatment erythema. The results of this study 
collaborate the results of Young's investigation; both regimens produced similar 
clearance levels, a greater number of treatments were required for the lower 
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dose regimen but a lower overall cumulative dose is achieved. The lower dose 
regimen also produced less potential for painful erythema (twice less likely) 
making this regimen more favourable. There were no significant differences 
between remission lengths for either regimen. 
Studies have also been carried out in order to determine the minimal number of 
treatment sessions required per week in order to provide effective treatment. In 
1998 Dawe et al studied 9 patients receiving treatment 3 and 5 times per week. 
Half body suits were worn and treatment was administered until clearance was 
achieved. It was hypothesised that the 5 treatments per week regimen would 
be the most effective stimulating clearance with fewer UVB exposures and a 
lower cumulative dose than the 5 times per week regimen. The study indicated 
that 5 treatments per week clears psoriasis quicker (35 days rather than 40) but 
at the expense of a higher cumulative dose and more treatment sessions 
(median 23.5 treatments for the 5 treatments per week and 17 sessions for the 
3 treatments per week). Painful erythema was also more likely with the higher 
weekly treatment regimen and there was no significance in the relapse time. 
Therefore, in order to reduce cumulative doses and treatment session 
numbers, 3 treatment sessions per week is more suitable. Studies continue to 
be performed in order to determine a safer and more therapeutic protocol and 
this study also aims to provide a deeper insight into narrow band UVB 
phototherapy. 
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1. 'fJ@ Outline Of Wiy Srcudy. 
Exposure doses are increased during the course to maintain an effective 
radiation dose at the epidermal basal layer as the skin adapts by hyperplasia 
and melanin pigmentation. The algorithm we use to increase exposure doses 
on subsequent treatments is based upon what is known about the adaptation of 
the skin following repeated exposures to broadband sources of ultraviolet 
radiation, as described above. However, we are using the TL01 narrow band 
fluorescent lamp and whilst this lamp has been designed specifically for the 
treatment of psoriasis, no established regimens for its use exist and it is likely 
that our present regimen is sub-optimal. The purpose of this study is to 
investigate how the erythemal response of the skin changes during a course of 
TL01 phototherapy in order to develop an effective regimen. 
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2. 'i Paiietnt Population 
Over the period of one year, 58 patients (aged between 18 and 72 years, mean 
44 years; 28 female) referred to Dryburn Hospital Phototherapy Department for 
TL01 UVB treatment took part in the study. The majority of patients were being 
treated for psoriasis, however, 15 patients were diagnosed otherwise; 4 chronic 
superficial scaly dermatitis, 4 polymorphic light eruption, 4 lichenoides chronica, 
1 pruritis, 1 eczema and 1 chronic superficial scaly dermatitis. 
2.2 TL()1 Phototherapy Unit 
Patients were treated in a whole body unit incorporating 48 Philips TL01 lamps 
(Canterbury instruments). The narrow band TL01 lamp is a relatively new 
addition to lamps available for phototherapy. It has an emission spectrum 
peaking at 311nm with a bandwidth of 2nm. The lamps were 2m in length 
mounted in 6 rectangular panels, the panels being arranged in a hexagon 
which constituted the treatment unit. Each panel incorporated 8 lamps 7.5cm 
apart. (see Fig 2.1 ). There were two doors to the unit incorporated into the front 
of the machine so that the UVB radiation was uniform around the patient and 
the patient was completely enclosed in the machine. Within the unit there was 
an emergency cord to enable the patient to stop treatment at any point if 
necessary. The doors were also able to open from the inside and this too 
stopped treatment if required. The exposure time for the patient was entered 
into the unit via a separate electronic timer located to the side of the machine 
and a mechanical backup timer was also set to prevent over exposure from 
occurring. 
2.3 Whole Body Phototherapy TL01 Regime 
UVB exposure produces erythema, which peaks 8-12 hours later and normally, 
fades within a few days. Therefore the sessions are normally given at least two 
days apart. The erythema produced from ultraviolet radiation limited the 
Susan Layton MSc Thesis 43 
exposure dose that could be given to the patient at any one time. Therefore, 
the treatment was fiactionated and given, usually, over a period of 8 weeks. 
The duration of the treatment course depended upon variables such as the 
extent of the condition, the response of the skin and the attendance of the 
patient. 
Exposure doses were increased during the course of the treatment in order to 
maintain an effective radiation dose at the epidermal basal layer as the skin 
adapted to the radiation by hyperplasia and melanin production. 
The regimen used in Durham Phototherapy Department was based upon 
knowledge of skin adaptation upon exposure to broad band UVB since narrow 
band UVB, designed specifically for the treatment of psoriasis, is a relatively 
new concept with very little published evidence on the relationship between 
exposure and skin adaptation. 
Patients admitted for a course of treatment were prescribed the course for 
(usually) 2 or 3 months. 38 patients were prescribed a course of 2 
treatments/week and 18 patients were prescribed 3 times/week. 1 in-patient 
was treated 5 times/week and 1 in-patient was treated 7 times/week. 16 or 24 
treatments were usually administered. A measure of photoadaptation, 
expressed in terms of the minimal erythema dose (MED), was determined 
between 1 and 13 times, with a mean of 5. Whole body exposure doses were 
increased logarithmically and recorded on the patients' record chart, which was 
designed for ease and accuracy, containing a predefined protocol for the 
patient based upon their response to the previous treatment. Initial treatment 
was given at 0.3 J/cm2, increasing by 0.2 J/cm2 until erythema was noted, 
normally this occurred at 0.5 or 0.7 J/cm2 Once erythema had occurred doses 
were initially reduced and thereafter increased by fractional increments as 
treatment progressed. The initial increment was 30%, falling to 20%, 10% and 
3% by the sth, 10th and 20th subsequent exposure, respectively. If moderate 
erythema occurred or if patients missed 2 or more treatments, empiricai 
changes to the regime were applied {see appendix 1). 
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2.4 Phototesting apparatus 
The phototests were performed using a single Philips TL 40W/01 lamp housed 
in a fully enclosed luminaire. Surrounding the lamp was a polycarbonate lamp 
diffuser, which was opaque to UVB radiation; therefore additional shielding was 
not required. Within the lamp diffuser there were 10 apertures, regularly 
spaced, each 8mm by 12mm. The apertures were designed to allow a range of 
doses to be administered simultaneously. One aperture remained open and the 
remainder were backed with metal foil, perforated with a grid of holes that were 
differing in size (Fig 2.2). The foil used allowed transmission of UV and did not 
vary with temperature, wavelength or the lifetime of the equipment. Each 
aperture increases the exposure dose by 26% giving a dose range of 8:1. The 
lamp was fitted with a digital electronic integrating dosimeter which terminated 
irradiation when the desired dose in the open aperture was reached. lrradiance 
from the lamp changed, depending upon factors such as temperature, lamp 
age and main supply voltage. The lamp was supported on a wall at an 
adjustable height to allow access to the outer aspect of the upper arm. It was 
situated in a small enclosed room in order to give the patient a sense of privacy 
and therefore encourage the patient to co-operate and produce the best results 
possible. 
2.5 Phototesting technique 
An initial phototest was performed prior to the patient's first treatment. The 
outer aspect of the patients upper arm was irradiated using the technique 
described previously. The irradiation site was then covered with a sheet of UV 
opaque card. The patients were given their whole body treatment and the card 
was then removed from the patients' arm. On the second visit to the 
department, 1 - 7 days later (mean 3 days), the just perceivable erythema on 
the upper arm was determined using visual assessment (Fig 2.3). Ideally, 
erythema threshold should have been determined 24hours post-test as it is 
known that UVB erythema is maximal 7-24 hours after exposure. This, 
however, was not possible due to the nature of the study where patients are 
involved. It is inevitable, therefore, that the accuracy of the results will be 
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decreased through the inability to acquire accurate readings at the most 
idealistic time period. However, because large numbers of patients were used 
in the study and because readings were always taken under the same 
environmental conditions all inaccuracies have been minimalised as for as 
physically possible. In order to achieve reproducibility, the assessment was 
always performed in the patients' cubicle, where the light was of constant 
illuminance. The patients were given their second whole body irradiation with 
no shielding over the phototested area to allow full treatment to occur. 
Phototests were repeated on several occasions during the subsequent 
treatments in order to determine the effect of narrow band UVB radiation upon 
skin adaptation. 
In order to determine if the LOW range (1.5 J/cm2 at the open aperture) or the 
HIGH range (3 J/cm2 at the open aperture) should be administered the 
following strategy is employed: 
o if the previous dose range was lOW and 3 or more dose sites showed 
erythema on the last visit the dose range was set to LOW 
o if the previous dose range was LOW and only 1 or 2 sites showed erythema 
on the previous test, the range was set to HIGH. 
o if the previous dose range was HIGH the dose range was kept at HIGH 
The initial phototest was always set at LOW but exceptions were made if the 
patient was not Caucasian or if extremely tanned, where the phototest started 
on HIGH. Personal observation has shown that patients with psoriasis do tend 
to have a greater tan than the average British person which is probably due to 
the positive effect that UV radiation has upon the condition. Therefore tanned 
patients were included in the study. However, if patients were particularly 
tanned (beyond what we would subjectively consider to be the 'normal' range). 
They were excluded from the study. Inclusion of such subjects would alter the 
results and lead to false conclusions. 
For each phototest care was taken to ensure that the test was not performed 
on skin which had already been used for the test and the right and left arm 
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were used alternately. This was done through recording phototest positions on 
a chart (see appendix 2). 
All information was documented both in a written record sheet and on computer 
using a spreadsheet prepared by myself using Microsoft ExceL The patients' 
record sheet provided the following details: 
name 
age 
sex 
frequency of treatment 
any nonattendances or cancellations. 
And for each phototest: 
days since last treatment 
number of treatments already attended 
the range setting on phototesting apparatus 
the arm used 
days MED read following the test 
MED (number of sites where erythema was present). 
MED (J/cm2) 
Each phototest was also recorded on computer so that collective data analysis 
could be performed and the information was readily available for statistical 
analysis. The data was analysed using MED ratios, which are expected to 
increase as skin adaptation occurs. 
MED ratio = MEDn /MEDo 
MED0= baseline minimal 
erythema dose measurement. 
MEDn = minimal erythemal 
dose after n number of 
treatments. 
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The MED ratio determines the extent of photoadaptation which has occurred 
since the initiation of the treatment course. It is a measurement of the increase 
in adaptation to UVB radiation due to the treatment administration. 
The aim of the project was to develop a skin adaptation model. It is known that 
UVB leads to hyperplasia and decreases in UVB levels lead to skin thinning. 
During UVB therapy, skin is actively thickening after UVB exposure and 
thinning between treatments, particularly if there are several days between 
exposures. Analysis of the data was aimed at providing a mathematical model 
that will enable optimum doses of UVB to be administered throughout the 
course particularly if treatments are missed or delayed (see appendix 2 for 
record sheet). 
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Fig 2.1 The TL01 whole body phototherapy unit used for treatment 
Susan Layton MSc Thesis 49 
Fig 2.2 The phototesting apparatus containing metal foil attenuators that 
allowed simultaneous delivery of 10 different doses of UVB 
Fig 2.3 An example of the graded erythematous reaction 24h after 
phototesting. The MEDin this patient was assessed as 0.47 J/cm2 
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3.1 Descriptive Statistics 
A total of 58 patients were enrolled and 330 MED measurements were made, 
272 of which were during treatment (MEDn) and 58 baseline measurements 
were made.(MEDa). The term MEDn indicates the MED after n treatment 
sessions. For each patient tested, the diagnosis was recorded (Table 3.1) 
along with the duration of treatment, number of treatment sessions and 
cumulative doses. 
TABLE 3.1 Summary of Phototherapy Course (values are medians) 
Diagnosis Number of Duration Number of Cumulative 
patients (weeks) sessions dose(J/cm2) 
-----------·---------------·---------·-------------------------·-------------------
Psoriasis 43 8 16 16 
CSSD 
PLC 
PLE 
Eczema 
5 
5 
4 
1 
7 
6 
7 
4 
16 
12 
16 
9 
17 
11 
9 
3 
Prior to treatment the baseline measurements (MEDo) were made and 
continuous assessment of the tolerance was made by repeating MED 
measurements (MEDn) following n treatment sessions. A summary of the 
phototests performed is shown in Table 3.2. 
TABLE 3.2 Summary of Phototests 
No. phototests during treatment course No. Patients 
--·------------------------------------------
~3 12 
4-6 29 
7-9 14 
10-12 3 
TOTAL 58 
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When the skin is exposed to UV radiation photoadaptation occurs, this involves 
epidermal hyperplasia and pigmentation. If the skin is not exposed to UV 
radiation the epidermis thins and depigmentation occurs. Tolerance is a 
measure of the relationship between these two processes. 
Tolerance of the skin can be described in the following model: 
tolerance = ( photoadaptation )( recovery ) 
and can be expressed as: 
T n = {MEDn}/ [ME Do] 
It is expected that the recovery time becomes more significant as the time 
between exposure increases. In order to examine this, the difference in 
tolerance between successive MEDs was determined (~MED) and the number 
of days that have elapsed since the previous phototherapy exposure was 
plotted below. Association analysis showed no relationship between these 2 
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variables (Spearmans coefficient of rank correlation, P = 0.3). 
Susan Layton MSc Thesis 52 
The data can be divided into 2 groups 
o ~MED values where the previous exposure was 5 days or less 
o ~MED values derived when more than 5 days have elapsed, due to the 
patient missing one or more treatment sessions. A Mann-Whitney test 
showed no significant differences in median values for the 2 AMED groups. 
3.2 Derivative of a Mathematical Model for Adaptation. 
There was no significant relationship between the relationship between the 
elapsed days since the previous phototest and the d.MED for those whose last 
treatment was <5 days and those whose treatment was >5 days. Therefore 
tolerance can be modelled using the following equation: 
T n = 1 + A [ 1 - exp (- A.n) ] 
where A. is a parameter representing the rate of adaptation. 
Iterative regression analysis was applied to the pooled set of patient data to 
determine the coefficients A and 'A. In this technique, the coefficient A is 
'guessed' so that the above equation can be transformed into a linear form: 
log [ 1 - (T n - 1 ) I A ] = 'An 
The coefficient 'A is obtained by linear regression and a 'goodness of fit' statistic 
calculated. The process is repeated by choosing the value of A which gives a 
minimum in this statistic. 
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3.2.1 Fitting the Model to The Experimental Data 
The mean values (± 1 sd) of T n at each treatment session were calculated and 
plotted in the following Figure. 
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From the regression analysis, 'A and A were calculated, giving an expression for 
tolerance as: 
Tn = 1 + 3 [1 - exp (- 0.03n)] 
From the expression it can be shown that the maximum mean tolerance is 4 
(1+3). This value is less than that determined from studies derived from 
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broadband UVB lamps. In such studies the range has been 4.7 - 9.5, 
depending on the skin type of the subject. T n was then used to revise the 
protocol for UVB narrowband phototherapy administration. 
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The data obtained in this study indicate that the differences in adaptation 
between broadband and narrowband UVB are only slight and therefore 
treatment protocols intended for broadband UVB treatment can be used during 
treatment with narrow band lamps. Narrow band lamps, however, appear to be 
more intensive in their therapeutic effects and lead to increased potential for 
excessive erythema, discomfort and inflammation. The study also enables a 
protocol of treatment to be produced that will enable administration of radiation 
at a higher efficiency with a smaller cumulative dose. The length of exposure is 
reduced per treatment and therefore the overall cumulative dose is also 
reduced. 
4. 1 Clinical trial 
In order to determine the extent of improvement the 'new' protocol produced a 
clinical trial was developed which involved random allocation of patients to 
either the new protocol (yellow group} or to the pre-exisitng regimen (green 
group). 
The clinical trial was carried out to compare a low dose regimen, based upon 
data derived from this study, to the usual protocol used in Dry-burn Dermatology 
Department. 
A similar type of study was performed in 1998 by Hofer et al, comparing the 
therapeutic effects of 'near and far' narrow band UVB phototherapy. Patients 
were treated 3-5 times/week and 1 half of the body was exposed to 70% of the 
MED (near exposure) and the other half was exposed to 35% of the MED (far 
exposure}. Doses were increased by 40%, 20% or not at all depending if 
erythema was not present, only slightly present or very obvious, respectively. A 
severity index was recorded for each patient once a week, based upon 
desquamation, infiltration and percentage coverage. 11 patients completed the 
study and analysis of the courses indicated that both regimens were successful 
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in clearing psoriasis. The far regimen required 4 more treatments than the near 
regimen and the far regimen still produced similar responses but with less 
cumulative doses of UVB. Hofer et al concluded that overall the far regimen 
was most appropriate in treating psoriasis and other skin conditions. 
In this clinical trial 48 patients were employed and randomly given either 
treatment regimen. 23 patients received the revised protocol (yellow group) and 
25 patients received the usual treatment course (green group). The information 
was collected over a period of 6 months and the initial minimal erythemal dose 
was recorded (usual range 0.5-0.9 J/cm2. Any excessive erythema that was 
encountered was noted and cumulative doses were calculated. 
Prior to initiation of treatment each patient underwent a preassessment using 
clinical scores to determine the severity of the condition. The recorded scores 
were based upon the extent of psoriasis on the arms, trunk and legs. ( 1 =severe 
2= moderate 3 = mild) Scores were then totalled so that 3 was most severe 
and 9 was most mild. Post treatment scores were also collected by the nurse. 
The post treatment scores were based upon the % clearance that occurs in 
each area. 
During the study the following data were recorded: 
e Number of treatments per week 
• Top row dose 
• Cumulative dose 
• Total number of treatments 
• Pre-treatment severity score 
• Post treatment severity score 
• The number of excessive erythemas 
In both regimens exposure was increased logarithmically until erythema was 
seen 48-72 hours later, i.e. on the patient's ne>.i visit. The radiation dose was 
then reduced and increased at a more gradual rate to accommodate the 
patient's skin tolerance rate. 
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The protocol for the green group had initial treatments of 0.3, 0.5, 0.7 and 0.9 
J/cm2. The patient moved across the chart until erythema was experienced, the 
next dose was taken as 80% of this dose and the further treatment doses were 
increased logarithmically. The yellow chart produced exposure doses that were 
similar but exposure increments were increased at a much slower rate. This 
resulted in a lower risk of erythema, discomfort and burning. If the trial was 
successful it could provide evidence that the protocol is effective. It will provide 
a protocol with a higher efficiency and a smaller cumulative dose. The 
treatment times will be reduced per treatment session and there will be less 
possibility of excessive, painful erythema, and potential carcinogenicity. 
All other variables were maintained during the trial in order to enable ac.curate 
comparisons to be made. In both regimens exposure doses allowed continual 
radiation at the epidermal basal layer and upon discharge, the severity of the 
patients' condition was established and related to the pre-treatment score. The 
following scoring system was used: 
e -1 worse 
@ 0 no change 
@ +1 
0 +2 
~ +3 
moderate improvement 
good improvement 
very good improvement 
Both regimes were prescribed for either 2 or 3 months and patients could have 
been discharged earlier if the condition had significantly improved. Discharge 
depended upon the opinion of the nursing staff at the time of the appointment 
and is confirmed by the doctor in charge. This prevented the patient from being 
exposed to more radiation than was necessary and therefore kept the 
cumulative dose to a minimum. 
4.2 Results 
The regimen used for each patient was selected randomly and the study 
involved both male and female patients. The conditions of the patients were 
Susan Layton MSc Thesis 58 
psoriatic only and severity ranged from 3-9 (average 6). On completing the 
treatment a second clinical score was collected. The post treatment was an 
indication of improvement and the range obtained was from 3-9 (average 6). 
Possible scores are 3 worse, 0 no change, 3 moderate, 6 good and 9 very 
good. Ideally, to eliminate bias, staff members should have been unaware 
which treatment regimen the patient was undertaking but this was unavoidable. 
4.2.1 The Green Group 
The green group of patients received the original phototherapy regimen and 
were treated for 6.5-13 weeks (median 8 weeks). After completion of the 
treatment course the severity score raised from 6 (range 3-9) to 7 (range 0-9). 
The average top row dose which produced the initial erythema was 0. 7 J/cm2 
(range 0.3-0.9) and the patients were subjected to 13-24 treatments (median 
16 treatments). The median cumulative dose was 16.9J/cm2 varying from 6.7-
49.6 J/cm2 (Table 4.3). 
Table 4.3 Summary of clinical trial data 
Variable Green Yellow P~value 
meduan (range) median (range) 
Weeks of treatment 8 (6.5-13) 8 (3.5-12) not significant 
Top row dose (J/cm2) 0.7 (0.3-0.9) 0.7 (0.3-0.9) not significant 
Total dose ( J/cm2) 16.9 (6. 7-49.6) 12.7 (2.1-21.5) 0.008 
No. treatments 16 (13-24) 16 (8-23) not significant 
Pre-treatment score 6 (3-9) 6 (3-9) not significant 
Post-treatment score 7 (0-9) 6 (3-9) 0.02 
4.2.2 The Yellow Group 
The yellow trial patients underwent treatment with a protocol devised from the 
results of this study. The median number of weeks of treatment given to 
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patients in this group was 8 (range 3.5-12), consisting of 16 treatments (range 
8-23). The pre-treatment and post-treatment score was 6 (range 3-9) and the 
top row dose was 0.7J/cm2, ranging from 0.3-0.9J/cm2. The median cumulative 
dose was 12.7 J/cm2 (range 2.1-21.5J/cm2) and during the course 22 patients 
experienced no erythema and only one patient was subjected to burning (Table 
4.4). 
Table 4.4 Incidence of burning 
No. Bums 
None 
P-value (Fisher exact test) 
~.3 COMCLUS801M 
Green grrolUip 
18 
7 
0.05 
22 
1 
The two groups of patients were well matched in terms of total pre-treatment 
scores and both groups consisted of a comparable number of patients. 
Therefore the results of the green and yellow trials can be compared and the 
following conclusions can be drawn: 
o There was no significant difference between the number of weeks of 
treatment administration for both groups. 
o There was no significant difference between the top row dose for both 
groups. 
o There was no significant difference between the number of administered 
sessions per week for both groups. 
o Patients in the yellow group received a lower cumulative radiation dose 
than the green group (P=0.008). 
o Patients in the yellow group experienced significantly less episodes of 
burning than the green group. 4 patients in the green trial experienced 
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one burn and 3 patients experienced two burns. In the yellow group only 
one patient was reported to have experienced one burn. 
o The improvements of the patients' conditions were greater for subjects in 
the green group than in the yellow group as measured by the post-
treatment scores. 
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5.1 Reliability of MED determination 
The MED determinations were carried under the same environmental 
conditions, including ambient illumination, throughout the study in order to 
minimise random uncertainties and increase the accuracy of the study. Each 
MEO was recorded by determining the number of sites that produced 
ejfthema. As far as possible I ensured that I was available for MED 
determination to minimise inter-observer bias. However, occasionally I was not 
present to assess the MED which was left to a member of nursing staff who 
had been previously shown how to assess MEDs. 
Other difficulties arose from the differences in skin types. Patients of varying 
skin types pigment to different degrees and some patients presented erythema 
that had already reached a maximum and was deteriorating, whereas in other 
patients the erythema was still maximal. During the MED recordings I assumed 
that this would cause problems to the study and skin types would have to be 
considered to produce viable results. However, analysis of the data (see 
chapter 3) clearly indicated that skin type did not significantly effect the results 
and did not need to be considered when presenting a protocol for treatment. 
Personal tolerance variations are considered through the way in which 
individual patients move through the treatment chart and this has proved to be 
sufficient. I also thought that the time period between performing the test and 
reading the results may affect the data because erythema deteriorates with 
time but upon analysis this did not prove to be significant and it was not 
necessary to include them in the model for skin adaptation. 
5.2 Fitting The Data To The Model 
The aim of the study was to determine an effective regime for the treatment of 
skin conditions such as psoriasis using narrow band UVB phototherapy. The 
rate of adaptation and the maximum tolerance was found to be significantly 
lower than expected through studies involving broad band UVB and the mean 
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maximum tolerance was found to be 2.6, reached after 40 treatments at the 
current administration protocol. Previous studies using broadband UVB lamps 
found the tolerance level to be 4. 7 - 9.5. The protocol used in the department is 
based upon these values and as a result it is often found that painful erythema 
results during the course of treatment. This can be explained using the results 
of the experiment because they indicate that the protocol chart increases the 
rate of UVB administration too rapidly and at a significantly higher rate than the 
rate of skin adaptation, therefore, too much radiation is being administered 
causing the erythema which is commonly seen. 
Cumulative doses of radiation vary from 0.1 - 87.9 Jcm-2. This value depends 
upon the number of treatments and the level of radiation administered during 
each treatment that is directly related to the tolerance level of the patient 
Patients move across the chart from left to right during the treatment course 
until they experience the initial erythema then the patient proceeds down the 
chart moving towards the left (lower doses) only if necessary. The data 
collected during the course shows a wide variability of results, however, a 
pattern has emerged that indicates the level at which the 'average' individual 
adapts to narrow band UVB radiation. The variability of results will depend 
upon skin type, duration of treatment, number of treatment sessions, the period 
of time over which treatment occurs, the cumulative doses of the treatment, 
errors and the condition that is being treated. 
5.3 Variations With Skin Type 
The skin type of individuals is determined by establishing the amount of 
radiation that is required to produce erythema prior to the initial treatment. The 
protocol followed (see appendix 2) meant that the patients received increasing 
increments of radiation until the skin began to become erythemal. Erythema 
was usually found to be on the chest, stomach, back or thighs. At this point the 
course for that particular patient was changed, to follow a more gradual 
regimen in order to prevent overexposure leading to severe erythema 
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Skill'D Type 
1 
2 
3 
4 
Property 
always burns, never tans 
sometimes burns, sometimes tans 
rarely burns, usually tans 
always tans, never burns 
The majority of patients attending for UVB treatment were of the skin types 2 
and 3, which means they could withstand some quantity of radiation before 
becoming burnt. A large number of patients were being treated for polymorphic 
light eruption and 4 participated in the study. For these patients the radiation 
had to remain low but it was important to include these patients in order to 
provide a protocol that could provide a regimen to suit everybody's needs. 
These patients are not only extremely sensitive to the suns radiation but, unlike 
the majority of psoriatic patients who tend to find the sun therapeutic and spend 
a long periods of time outdoors or on sunbeds, they generally choose not to go 
outside and as a result their skin is extremely sensitive and prone to erythema. 
Patients of skin type 4 included those who were naturally extremely pigmented 
but in certain cases it was also obvious that their skin had become thickened 
and very pigmented due to continuous exposure over the years in a personal 
effort to treat themselves with sun or artificial radiation. Thus, the skin would 
already be adapted to a certain degree before the initial treatment and higher 
radiation levels were required to produce an effect at the base of the epidermis. 
So although there is a maximum dose of radiation which would generally be 
exceeded in phototherapy additional natural exposure is unknown. Patients 
who undergo radiation treatment of this type should therefore be warned about 
the dangers of exposure to radiation generally (e.g. carcinoma, melanoma etc.) 
as well as the added risks through treatment. 
The patients who participated in this study probably will probably be 
representative of the population presenting in dermatology clinic throughout 
Britain and therefore the results of this study have a potential for the improving 
narrowband UVB protocols. Having analysed the data it has been found that 
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the rate of skin adaptation does not depend upon skin type and there is a 
significant pattern to tolerance development emerging. There is adaptation 
deviations and following 15 treatments the amount of adaptation varies from 
1.2 - 2.55. Deviations will be due to differences in cumulative doses, the 
differences in treatment numbers per week, inaccuracies in reading MEDs, and 
previous personal radiation exposures. Missing one or two treatments has not 
been found to be significant 
SA Umproving ~he Study 
More consistent results could have been acquired if I was able to ensure that I 
was available to read every MED. The perception of erythema varies from one 
person to another and therefore anomalies are inevitable if a different individual 
is recording the results. 
If all patients attended the same number of treatments each week this too could 
have improved accuracy, although the results do not find the differences in 
adaptation between those receiving treatment twice a week and those 
attending three times significantly different on average. Therefore, for the sake 
of the study if the number of treatments per week was kept constant it would 
mean that changes in tolerance resulting from missed treatments could be 
pinpointed more accurately and adaptation changes due to skin types may be 
more evident. 
If the phototest equipment was more portable and able to be strapped to the 
patients body during testing this would improve the test enormously because a 
lot of patients found it very difficult to maintain the same position for the period 
of time required (approximately 8 and 16 minutes). Often, particularly during the 
high dose (3J/cm2) exposure, patients would move their arm and the results 
became less reliable. The problem of people not holding their arm close 
enough to the machine also arose and straps would have ensured patients 
were positioned correctly for each test. Also, if the radiation could have been 
given over a shorter period of time this would have improved the accuracy of 
Susan Layton MSc Thesis 65 
the test by reducing the potential time that the patient is irradiated and therefore 
reducing the time available for movement. 
Patients who are exceptionally hairy should have had the hair removed 
because hair attenuates UV radiation to some extent thus making the patient 
seem more tolerant to the radiation than they actually are. The hair would have 
to be gently removed with scissors and not a razor, however, because shaving 
removes the top layer of dead epidermal cells, exposing the lower, more 
sensitive layers (for this reason shaving the patient is often used in 
departments such as ECG in order to produce a good electrical contact). 
The phototests were performed on the upper part of the arm because it was 
thought that this area is less likely to have been exposed to sunlight, even in 
the summer T-shirts cover the upper arm. However, in psoriatic patients, who 
generally improve in the summer, exposure of as much of the skin as possible 
tends to be the norm and the upper arm is therefore more tolerant than the 
stomach or buttocks. This alters the results because it means that the skin 
tested is more tolerant than was originally thought, but other areas of the 
patient are not as well adapted. This was considered in producing an 
alternative regimen in order to prevent the more sensitive skin of the torso 
becoming overexposed and excessively erythemal. In order to improve the 
adaptation data it might be more desirable to irradiate the skin of the inner 
aspect of the arm, the buttock, back or chest. It is important to use the least 
tolerable area of the body because these are the areas that become erythemal 
first and therefore it is these areas that prevent higher doses of radiation from 
being administered. It must be remembered that skin from different areas of the 
body have different thickness (see chapter 1) and therefore different parts of 
the body will react differently to radiation. For these reasons a series of 
simultaneous light tests on different parts of the body should have been 
performed so that a regimen that is related the entire body can be produced. It 
is the entire body that is to be treated after all. 
If the study was to be repeated the above point would be considered and 
several other alterations would be made. The opening times of the department 
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were 9:00am to midday and 1:00 to 7:00pm. This often proved difficult because 
I was only present in the department from 1:00 to 5:00pm. The majority of 
patients visited the department at similar times each week but attendance is at 
the patients convenience, which sometimes proved difficult to me because it 
meant I could not perform a phototest or personally read the patients' results. 
Therefore, upon repeating the study I would ensure I was available during all 
opening hours to carry out the phototests. 
The study was performed over a period of 1 year. During this time the 
department closed for holidays and patients had to reschedule appointments. 
However, this was difficult to fit into the mathematical equation because the 
equation is based upon being treated at regular intervals. If the study was to be 
repeated the results would be easier interpreted if the patients were advised to 
miss treatments instead of rescheduling them for an alternative day and this 
could then be easily analysed once the course is completed. 
5.5 Conclusion. 
The majority of studies that have been performed in the past used broadband 
UVB as their basis e.g. Young 1972, Anderson 1984. This study was aimed at 
collecting data that enabled a more efficient protocol to be produced for 
narrowband UVB, a protocol with reduced carcinogenicity and maximum 
efficiency. The data were collected over a period of 1 year to enable a wide 
range of patients to be tested and to produce a large pool of data. The data 
were analysed and a mathematical model was derived. The determinants for 
the model were not found to include skin type, sex or age and it was also 
established that missing 1 treatment (up to 7 days) did not significantly alter 
tolerance development. Therefore, there was no need to alter a patient's 
regime if he/she did not attend one treatment or cancelled an appointment. 
The study indicates that it is possible to significantly reduce the intensity of 
UVB radiation for each treatment course and only reduce the effectiveness 
slightly (P= 0.02). Pre- and post-treatment scores actually showed very little 
improvement in disease severity with the original protocol and no improvement 
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with the modified protocol. The possibility of reducing radiation doses when 
using narrow band UVB is because narrow band UVB is much more intense in 
its healing effect than broadband UVB. The fact that narrowband UVB 
produces erythema at smaller increments than broadband UVB indicates the 
reason why a significantly higher number of patients become burnt during the 
treatment course (28% green patient and 5% yellow patients). Through 
reducing the radiation dose, the revised protocol enables an efficient level of 
treatment to be delivered to patients without overexposure, thus keeping the 
amount of radiation to a minimum and therefore reducing the probability of 
carcinogenesis. 
The revised protocol was not significantly different in the number of weeks 
before treatment clearance, the top row dose or the number of treatment 
sessions during the course. 
Therefore, the mathematical model has enabled a protocol to be produced 
which has an improved safety profile: reduced potential for episodes of burning 
and reduced cumulative doses of UVB but the effectiveness of treatment was 
slightly reduced and questions concerning its efficiency should be answered 
prior to general adoption of the protocol for patient use. It may also be 
worthwhile following up this study by comparing the length of time the green 
and yellow patients remain in remission as this must also be considered in 
deciding if the 'new' protocol is a success. The conclusions drawn from this 
study also reflect the conclusions of Hofer et at (1998) and George at at (1998) 
who also performed high/low comparative studies and by pooling my results 
with those of Hofer and George further evidence is provided that suggests the 
lower dose regimen, which is less carcinogenic, would be more appropriate. 
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Appendix 1 
Phototherapy Treatment Regimen Tables 
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Begin treatment courS6 wflh a dose of 0.3 J/~. M ove across the first row until ,._ess Is seen 24 hours after expostJ(e. If the redness is tlqUivocaJ (le 
barely perceptible) give dose in row immediately below. If a definite redness is seen, give dose in row d!agonalfy to !ell. Aim to keep In thi~ column but 
move diagonally downwards left or right to reduce or accelerate treatment, respectively. Circle each dose that Is given. Tick I./I skin condition and redness 
columns approprlt~tely each time parlem attends for tre8tmenr. Write any relevant comments following exposure overpt~ge . 
Name: 
B No. o.te sig'd Slcin condition 
I 
-
t ~ 
key: I worse; • no change; I improved: 9 clear 
8t IJtillr;n.,. ,_ ~ JV/v ,,t1 
O.te 
alg'd_ . . . 
-
Dose . o.3~ 
J lcm2 /I 
--....... 
- -
~-- .. ,..... 
' 0 .1 0.2 
0 .1- 0 .2 
0.2 0.3 
0.2 0 .3 
0.2 0.3 
0.2 0 .3 
0.2 0 .3 
0 .3 0.4 
0.3 0.4 
0 .3 0.4 
0.3 0.4 
0.3 0 .4 
0 .3 0.4 
0 .3 _ 0.4 
0 .3 0.4 
o.a· ·. 0.5 
0 .3 
0 .3 
0.3 
0.3 
0 .4 
0.4 
0.4 
0.6 
0.6 
0.6 
0.6 
0.5 
0.5 
0.5 
; .  ~ . 
···' 
... ' " 
·-
. . 
... - o .5- ... - 0.7-
--
-0.9 
./ I ./ I ./ I 
Jt~tM 
- - - - - -
' todl't' f'fiHtJ 
- - - - -
0 .3 0.4 0.5 0 .8 0.8 0 .7 
0.3 0.4 0.5 0.8 0 .6 0 .7 
0 .3 0 .4 0.5 0 .6 0 .7 0.8 
0.4 0.6 0.6 0.7 0 .7 0 .9 
0.4 0.5 0 .6 0 .7 0.7 0.9 
0.4 0.5 0 .6 0.8 0.9 1.0 
0 .4 0.6 0.7 0 .8 0.9 1.0 
0.5 0.6 0.7 0 .8 0 .9 1 .1 
0.6 0.6 0.7 0 .9 1.0 1.1 
0.5 0.6 0.8 0 .9 1.0 1.2 
0.5 0 .7 0.8 0.9 1.1 1.2 
0.5 0.7 0.8 1 .0 1 .1 1.2 
0.6 0 .7 0.8 1.0 1.1 1 .3 
0 .8 0.7 0.9 1.0 1.2 1 .3 
0 .6 0 .7 0 .9 1.0 1.2 1 .3 
0 .6 0.8 0.9 1.1 1 .2 1.4 
0 .8 0.8 0.9 1.1 1.2 1.4 
0 .8 0 .8 0 .9 1.1 1.3 1.4 
0.8 0.8 1 .0 1 .1 1 .3 . 1.5 
0.8 0.8 1.0 1 .2 1.3 1.5 
0 .8 0.8 1.0 1.2 1.3 1.6 
0 .7 0 .8 1.0 1.2 1.3 1.5 
0.7 0 .9 1.0 1.2 1.4 I R 
Cumulative d056 ............ Jicm' Total no. treetment seulons: .......... 
Begin treatment course wtlf> a dose of 0 .3 J/crri'. Move across the rnt row until rtKiness Is saen 24 hours llflf1r 9JQ:)OSIMll. If the redness is equivocal (le 
barely perceptible} give dose in tow immediately below. If a definite redness is seen, give dose in tow diagonally ro lett. A im to l<t#Jf' in this co/IJmn but 
move diagonally downwards left or right to reduce or accelerate trelJtmenr, respectively. Citcle each dose that is given. Tick (.I J skin condition and redness 
columns appropriately each time patient attends tor treatment. Write any relevant comments tollowmg exposure overpage. 
Date 
Name: 
sig'd 
Dose 0.3- M'"""' 0 .5- .... .-.. 0.7- ... ..,.., -0.9 
~No. Date sig'd Skin condition Jl?f'' ,/ I ,/l ,/ . 
,/ ' 
.. 
·-... 
- - - -
....... 
-
...... 
......, fYINIIl 
-
• t @ 
... _ 
- - - - - - --
' 
-..;. 0.1 0 .2 0.2 0.3 0.4 0 .5 0 .6 0 .6 ' 
I 
0.2 0 .2 0 .3 0 .4 0.5 0 .7 0.7 0 .8 
. ' 0.2 0 .3 0.4 0.5 0 .6 0.8 0.9 1.0 ' 
0.3 0.4 0.5 0.6 0.8 1.0 1.1 1.2 I 
·- ' 
' 0.3 0.4 0.6 0.7 0.9 1.2 1.3 1.5 
0 .4 0 .5 0.7 0 .9 1.1 1.4 1.5 1 .7 
0.4 0.6 0.8 1.0 1.2 1.6 1.7 2 .0 
0.5 0.7 0.9 1 .1 1.4 1.8 2.0 2 .2 
0 .5 0 .7 1.0 1.2 1.6 2.0 2.2 2.5 
0.6 0.8 1.1 1.4 1.7 2.2 2.5 2.7 
0.6 0.9 . 1 .2 1 .5 1.9 2.4 2.7 3.0 
' 0 .7 1 .0 1.3 1 .6 2.1 2.6 2.9 3.3 
. 0.7 1.1 1.4 1 .8 2.2 2.8 3 .1 3.5 
0 .8 1.1 1.4 1.9 2.4 3.0 3.3 3.7 
-
0.8 1.2 1.5 2.0 2.5 3.2 3.5 4 .0 
, 
' .0.9 1.3 1.6 2.1 2.6 3.3 3.6 4 .2 
' 
.; 0 .9 1.3 1.7 2 .2 2.7 3 .4 3 .7 4 .4 . 
1 •1.0 1.4 1.7 2.3 2.8 3.5 3 .8 4 .5 
-~ 1.0 1.5 1·.8 2.4 2.9 3.6 3.9 . 4.6 
' " ' .. l 1.1 1.5 1.9 2.4 . 3.0 3.7 4.0 4.7 
' 
,. 1 .1 1.6 1.9 2 .5 3.1 3.8 4.1 4.8 . . 
1.2 1.6 2.0 2.5 3.1 3 .9 4 .2 4 .9 
1.2 1.7 2.0 2.6 3 .2 4.0 4 .3 5.0 
. 
Key: I worse; • no change; t improved; @ cleat 
• &Jitl~ ..... H' -~"""' ,,; Cumulative dose ..... .. ..... J/cm' Total no. treatment sessions: .. ....... . 
' 
•I 
Data 
' 
Begin treatment course with a dose of 0.3 J/Cn(. Mawt across the first row until redness Is SMn 24 
hours affer 8Xp0$1Jf11. If the redness Is equivocal (le batsly pen;eptible) give dose In row immediately 
below. If a definite red11sss is SMn, give dose In row diagonaly to ~ Aim to ksep In this column but 
rncwe diagonlllly downwards lett or right ' to rwJuce or ·acceJsrate'traatment, respectiVely. Circle sech 
dose that Is given. TICk (or) sldn condition colUmn appropria16ly each time paliflnt attsnds for 
trNtment. WrMe any relevant comments following exposun 0Vf111J8116. 
Dallo 
elg'd 
DoN 0.3- .. - o.s- .. - 0.8- .. - -1 
•lg'd Sldn condition J/crrl , l ( l , l , l 
-· - - -
..... 
-
...... 
...,_ 
l t - --
~ 
-• 0 0 - 0 1 
0.2 0.2 0.3 0.4 0.5 0.6 0.7 o.e o, -
--
0 
0.2 0.3 0.3 0.4 0.5 0.7 0.8 0.11 
0.2 0.3 0.4 0.5 o.if -- 0 "0."7 0.8 0.8 
0.2 0.3 0,4 0.5 0.6 , (!,8- 0.11 1.0 
0.2 0,3 0.4 Oo6 0.7 0.11 1.0 1.1 
Oo3 0.4 0.5 0.8 0.8 ,:o 1.1 1.2 
0.3 0.4 0.8 0.8 " Oo8' ?;O"' u - 1o3 
0.3 Oo4 Oo5 0.7 O.lt 1o1 1o2 1.-
0.3 0.4 0.8 0.7 0.9 102 1o3 1.5 
0.3 0.5 0.8 0.8 1.0 1.3 1.4 1o8 
0.4 0.5 0.7 0.9 1.1 1.4 1.5 ·1.7 
0.4 0.11 0.7 0.9 1.2 1.5 1.11 1.8 
0.4 0.8 0.8 1.0 1.2 1.8 1.7 2.0 
0,4 0.8 0.8 1.0 1.3 1.7 1.8 2.'1 
0.5 0.7 0.11 1.1 .• 1.4 1.8 2.0 u 
0.5 0.7 0.11 1.2 1.5 1.9 2.1 2.3 
0.5 0.7 1.0 1.2 1.6 2.0 2.2 2.5 
0.8 0.8 1,0 1.3 1.8 2.1 2.3 2.8 
0.8 0.8 1.1 1.14 1.7 2.2 2.4 2.7 
0.8 0.8 1.1 1.4 1.8 2.3 2.8 2,8 
0.8 0.8 1.2 1.5 1.9 2.4 2 . 7 3.1) 
0.7 0.11 1.2 1.8 2.0 2.5 ' 2.8 3.2 
0.7 1,0 1.3 1.7 2.1 2.6 3.0 3.3 
. 0.7 1.0 1.3 1.7 2.2 2.8 3.1 3.5 
0.8 1.1 1.4 1.11 2.3 2.9 3.2 3.8 
0.8 1.1 1.5 1.11 2.4 3.0 3.4 3.7 
0.8 1.2 1.!5 1.11 2.5 3.1 3.5 3.~ 
0.9 1.2 1.8 2.0 2.6 3.2 3.6 4.0 
0.9 1.3 1.8 2.1 2.7 3.4 3.7 4.2 
0.9 1.3 1.7 2.2 2.7 3.5 3.8 4.3 
1.0 1.3 1.7 2.2 2.8 3.8 4.0 4,'5 
1.0 1.4 1.8 2.3 2.9 3.7 4.1 4.6 
1.0 1.4 1 .II 2.4 3.0 3.8 4-.3 ' 4.8 
1.0 1.5 1.8 2.5 3.1 3.9 4.4 4.9 
Key: l worse; • no chqe; t irnpnwed; 0 clear 
-
-
-
Appe81ldox 2 
Phototest Exposure Record Charts 
Susan Layton MSc Thesis 70 
TlO 1 Phototesting Record Sheet 
Patient Name: ............................................. . Frequency: 2 I 3 times per week 
Sex: M I F Age: ........ . Medication: Yes I No 
Setttnng dose rrafl1lge 
If previous dose range was low and 3 or more sites showed erythema on last phototest, 
keep dose range set to low; 
OR if previous dose range was low and only 1 or 2 sites showed erythema on last 
phototest, set dose range to high; 
OR if previous dose range was high, keep dose range set to high. 
Aim to phototest patients on alternate attendances, and on the left and right arm, 
alternately. 
First attendance (pre-treatment MED) 
II Date of last treatment: nla Treatments so far: 0 Date today: 
I Dose range: low I high I Arm: left I right Cumulative dose Jlcm2 
0 
Date MED read: MED read by: 
MED: Mark a cross ( x) in the appropriate bo.x 
I highest dose 1 2 3 I 4 I 5 l s 1 8 9 l1o I lowest dose I 
Phototest: 2 
Date of last treatment: Treatments so far: Date today: 
Dose range: low I high Arm: left/ right Cumulative dose Jlcm2 
Date MED read: MED read by: 
MED: Mark a cross ( x) in the appropriate box 
II highest dose I 1 I 2 I 3 I 4 I 5 I 6 I 1 I 8 I 9 l1o I lowest dose II 
Phototest: 3 
I Date of last treatment: Treatment~ so far: Date today: 
I Dose range: low I high Arm: left I right I Cumulative dose Jlcm2 
I Date MED read: MED read by: I 
MED: Mark a cross ( x) in the appropriate box 
I highest dose· I 1 I 2 I 3 I 4 I 5 I 6 I 1 I 8 I 9 l1o I lowest dose I 
-
' I 
- .. 
. ' 
,_. 
., . 
' . 
~~@MJ tr . 
tfoRH 
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